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COMBINED GENOME-WIDE ASSOCIATION STUDIES OF CANNABIS 
DEPENDENCE AND PERSONALITY TRAITS 
MARK C. LOHSEN 
ABSTRACT 
Background: Cannabis dependence (CaD) and component behaviors of personality are 
highly heritable, but the genetic basis of these traits is poorly understood. Since several 
attributes of personality (e.g. neuroticism) are strongly correlated with cannabis use, we 
hypothesized that specific combined genetic underpinnings contribute to both CaD and to 
certain aspects of personality.  
Methods: Personality was quantified with the Revised NEO Personality Inventory that 
asked questions from the five personality domains. Personality information was acquired 
from 1931 African Americans (AAs) and 1517 European Americans (EAs). CaD was 
measured as a summation of the seven binary DSM-IV diagnosis symptoms within a 
separate set of 1311 AAs and 2752 EAs in the NIH-funded “Study of Addiction: Genetics 
and Environment” (SAGE). Genome-wide association studies (GWAS) were performed 
after filtering out single-nucleotide polymorphisms (SNPs) with low minor allele 
frequency (MAF) and poor imputation quality. The personality trait was used as the 
outcome in the primary data set while CaD was used in the SAGE data set. Meta-analysis 
was used to combine the results for both traits within and across ethnic groups. 
Additionally, while honing in on the personality / CaD comparison, the analysis further 
investigated component facets of the NEO domain most strongly correlated to CaD.  
  vi
Results: Genome-wide significant (GWS) results were obtained for EAs from the 
bivariate analysis of CaD paired with the extraversion domain (rs12534830, p=1.73E-08) 
near SEMA3D and paired with the vulnerability to stress facet, which is a component of 
the neuroticism domain (rs76021834, p=1.58E-08) within POR. GWS association was 
also observed with the vulnerability to stress facet considered as a single outcome in a 
SNP within the solute carrier gene SLC35F3 (rs12047995, p=3.55E-08) in the combined 
sample of AAs and EAs.  
Discussion: Notable associations with both CaD and several personality traits include 
SNPs from multiple semaphorin genes whose protein products are axonal growth cone 
guidance molecules. These SNPs were either within or proximal to SEMA3A, SEMA3D, 
SEMA6A, or SEMA6D, which have links to schizophrenia, as discussed in many other 
studies. Further investigation in independent data sets is warranted to confirm the validity 
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Genome-wide association studies are hypothesis-generating endeavors that seek 
to link a genetic marker with a phenotype. By design, they have the power to scan the 
entire human genome for possible links in an agnostic, unbiased manner without regard 
to prior hypotheses or findings. This approach is in contrast to a linkage method, which 
has the ability to scan the entire genome and at the same time requires multiplex families 
and has limited resolution. Other called positional mapping methods may not require 
families and do not consider the entire genome. Both linkage and positional mapping 
methods focus only on a specific region and are not as successful at characterizing multi-
factorial disorders such as psychiatric traits (Psychiatric GWAS Consortium 
Coordinating Committee, 2009).  
GWAS have identified genes previously established as disease-associated as well 
as novel associations with genes that would not have been candidates based on the known 
biology of the disease. GWAS have also pinpointed loci that are not even within genes. 
These scans have provided an unprecedented level of resolution – down to one single 
nucleotide. With all these benefits, it is important to note the pitfall of the vast amount of 
samples necessary to obtain true and accurate results. When conducting hundreds of 
thousands or even millions of genetic tests, there are bound to be many false positives. 
Sufficiently powered studies are able to prevent false positive results (Hunter and Kraft, 
2007).  
GWAS have and characterized novel biological pathways and provided critical 
therapeutic information. For example, carriers of risk variants at TCF7L2 are more likely 
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to fail sulfonulyurea therapy for type 2 diabetes mellitus than metformin therapy (Billings 
and Florez, 2010). In uncovering the mechanisms of physiological pathways, it has been 
gleaned that inflammatory bowel disease is thought to arise from dysregulation of 
intestinal homeostasis (Visscher et al., 2012). GWAS continues to be a valid and useful 
tool in the arsenal of genetic analysis. In this work, the technique was applied to the 
multi-faceted disorder of cannabis dependence (CaD).  
Cannabis is the most widely used illicit substance in the United States. An 
estimated 2.8% to 4.5% of the world’s population used cannabis in 2009 (Degenhardt and 
Hall, 2012). Despite these statistics, the abuse of the drug receives little attention in 
research field compared to alcohol and other major drugs of abuse. In the United States, 
residents of states with legal medical marijuana have a significantly higher risk of 
developing CaD (OR=1.81 (1.22 - 2.67)) (Cerda et al., 2012).  Therefore, further 
investigation into the mechanisms of its mode of physiological action is warranted.  
Cannabis is a versatile compound and has also been used in the clinic as a 
therapeutic for chemotherapy-induced vomiting and AIDS-related anorexia (Walsh et al., 
2003). Psychoactive cannabinoids (cannabis derivatives) have been shown to have a 
variety of benefits including the growth inhibition of a rat glioma cell line (I. Galve-
Roperh et al., 2000). In the realm of obesity, antagonists of the cannabinoid receptor CB1 
were reported to modulate food intake in rodents (Ravinet Trillou et al., 2003). In CB1 
receptor knockout mice, the receptor antagonist had no effect on food intake and further 
supported the hypothesis that cannabis receptors play a crucial role in food intake and 
diet-induced obesity.  
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In a young adult twin sample, 44% of the variance in liability to cannabis was 
linked to genetic factors while the remainder was linked to environmental factors 
(Lynskey et al., 2002). Genetic links to cannabis dependence (CaD) are poorly 
understood. A previous genome-wide association of CaD revealed suggestive evidence of 
association with the ANKFN1 gene. The findings were not genome-wide significant 
(GWS) (Agrawal et al., 2011).  
There is growing agreement among psychologists that personality can be divided 
into five major dimensions of neuroticism, extraversion, openness to experience, 
agreeableness, and conscientiousness (Costa and McCrae, 1991). These traits are 
enduring dispositions and major determinants of behavior (Terracciano and Costa, 2004). 
The Revised NEO Personality Inventory (NEO PI-R) can be used to estimate social and 
behavioral outcomes or psychiatric disorders. This version consists of the five domains, 
each divided into six sub-domains known as facets.  
Addiction to cigarette smoking was analyzed in the context of the personality 
domains within a sample of 1638 people (Terracciano and Costa, 2004). Current smokers 
scored higher than people who never smoked on neuroticism and lower on agreeableness 
and conscientiousness. There were no differences on extraversion and openness to 
experience. Within the individual facets, smokers were characterized by inability to resist 
cravings (high impulsiveness), search for stimulation (high excitement-seeking), lack of 
perseverance (low self-discipline), and lack of careful consideration of consequences 
(low deliberation). Similar results were obtained from another independent study in terms 
of the neuroticism and conscientiousness domain results for both cigarette smokers and 
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cocaine/heroin users (Terracciano et al., 2008). Marijuana users scored average on 
neuroticism and low on conscientiousness.  
GWAS of NEO personality inventory domains have yielded genome-wide 
significant results for openness to experience near the RASA1 gene and for 
conscientiousness in the KATNAL2 gene (Moor et al., 2012). Within the neuroticism 
domain, SNPs in the MAMDC1 gene were near GWS (van den Oord et al., 2008). The 
MAMDC1 protein is proposed to be involved in axonal guidance and neuronal migration. 
Further genetic links to personality traits will be reported in this present study. 
Substance dependence and personality characteristics are often linked. This study 
aimed to uncover genetic underpinnings common to both CaD and personality using a 




I. Subject Recruitment 
Subjects were recruited within two unique studies hereby referred to as: 1) 
discovery; 2) Study of Addiction – Genetics and Environment (SAGE). Subjects in the 
discovery sample were recruited from several locations (Table 1). Individuals were 
recruited primarily to study the genetics of dependence on cocaine, opioids, and alcohol. 
Ancillary traits such as CaD and co-morbid mental disorders were also analyzed. All 
information was asked in a large, computer-based, interview-style questionnaire known 
as the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). 
 
Table 1. Subjects within Entire Discovery Data Set. 
AA EA Total 
Institution Male Female Male Female 
Yale University 652 627 626 398 2303 
University of Connecticut 629 582 606 457 2274 
Medical University of South 
Carolina 95 193 85 76 449 
McLean Hospital, Belmont, MA 54 42 60 41 197 
University of Pennsylvania 297 147 20 10 474 
Total 1727 1591 1397 982 5697 
 
From the SAGE data set (publically available via application at 
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000092.v1.p1) 
(Bierut et al., 2007), subjects were analyzed based on their use of cannabis. Subjects from 
this study included individuals from the Collaborative Study on the Genetics of 
Alcoholism (Edenberg, 2002), the Family Study of Cocaine Dependence (Bierut et al., 
 6 
2008), and the Collaborative Genetic Study of Nicotine Dependence (Bierut et al., 2007). 
All individuals were unrelated. 
 
II. Diagnostic Procedures of CaD 
To diagnose CaD within both the SAGE subjects, questions specific to CaD from 
the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV were asked. In the 
discovery sample, these questions were covered in the SSADDA. These included details 
on withdrawal, tolerance, amount of time individual spent seeking the drug, etc. Answers 
to the seven questions were recorded as “yes” or “no” and the sum of the affirmative 
answers was termed the ordinal 7 trait. This quantitative trait analysis was chosen over a 
dichotomous case-control analysis due to the multiple advantages. It reduces mis-
classification, yields a more precise estimate of the severity of affection, and has greater 
power in a genetic study. Individuals with fewer symptoms were differentiated from 
individuals with multiple symptoms with a higher score on the scale.  
 
III. Diagnostic Procedures of Personality 
In the discovery sample, a personality score was determined via a paper 
assessment pertaining to the Big Five domains of personality (neuroticism, extraversion, 
openness to experience, agreeableness, and conscientiousness), each of which contain six 
individual facets (Goldberg, 1990) (Table 2). The assessment consists of eight questions 
for each of the six facets within all five of the domains for a total of 240 questions. 
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Table 2. The Five NEO Personality Inventory Domains with Their Six Facets. 
Neuroticism Extraversion 
Openness to 
experience Agreeableness Conscientiousness 
Anxiety Warmth Fantasy Trust Competence 
Hostility Gregariousness Aesthetics Straightforwardness Order 
Depression Assertiveness Feelings Altruism Dutifulness 
Self-
consciousness 















Personality scores were normalized with respect to age and sex within each overall 
domain and facet. Approximately 16% of individual response forms had several of the 
same answer in a row. These were determined to be unreliable and thus the personality 
data for these individuals were not used in the genetic analyses.  
 
IV. Genotyping 
 988,306 selected representative single-nucleotide polymorphisms (SNPs) from 
individuals in the discovery sample were genotyped on the Illumina HumanOmni1-Quad 
v1.0 microarray (Illumina, San Diego, CA, USA). The genotyping was performed at both 
the Yale Center for Genome Analysis and additionally at the Center for Inherited Disease 
Research for replication purposes. Genotypes were called using GenomeStudio software 
V2011.1 and genotyping module V1.8.4 (Illumina). The samples in the SAGE data set 
were genotyped on the Illumina Human 1M array containing a total of 1,069,796 SNPs. 
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V. Quality Control 
44,644 SNPs on the microarray, 135 samples with call rates <98%, and 62,076 
additional SNPs with minor allele frequencies <1% were excluded from the discovery 
analysis. After data cleaning and quality control (QC), 5697 individuals and 889,659 
SNPs remained for imputation.  
In addition to excluding SNPs for low call rate or low MAF, some individuals 
were excluded for duplicate genotype and phenotype information. Within the discovery 
data set, some genetic data of individual subjects exactly matched data from other 
individual subjects who claimed to be different people. When checking the sample, if the 
demographic data were the same for both matches, only one individual was randomly 
removed. If the demographics didn’t match, both samples were removed from the 
analysis. Sometimes, pairs of individuals reported themselves as related when their 
identity by descent (IBD) profiles from PLINK (Purcell et al., 2007) did not match. In 
these cases, they were then assigned to different families. If an individual pairing shared 
>25% alleles IBD, they were assigned to the same family. Male and female status was 
confirmed using a 20% X-chromosome heterozygosity threshold unless true identity 
could be determined. 
When correcting for related individuals and self-reported race in the discovery set, 
a principal components analysis (PCA) was performed using Eigensoft (Price et al., 
2006). In the discovery data set, this was performed on the entire sample using 145,472 
SNPs common to both the data set and standardized reference panels from HapMap3, 
which had individual data from European, African, and Asian descent. The first PC score 
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was used to distinguish AAs and EAs by a K-means (K=2) clustering algorithm (Hartigan 
and Wong, 1979). AAs and EAs were then analyzed separately throughout all studies. 
The second and third PCs represented residual ethnicity within these two major groups. 
In all future analyses within both the discovery and SAGE data sets, the first three PCs 
were used as a correction for ethnicity.  
 
VI. Imputation of Genotypes 
In a standard genetic analysis, around 1 million SNPs are genotyped from the 
individuals and around 30 million SNPs are used in the GWAS. The remaining 29 
million un-genotyped SNPs are approximated with mathematical probabilities of which 
specific SNP is in each locus. The output is a fractional value between 0 and 2 that 
represents the probability of the genotype expressed in terms of the number of minor 
alleles. The calculation is based on a reference panel of previously genotyped individuals 
and is known as imputation. This procedure tremendously reduces the financial costs of 
genotyping individual genetic markers. In this study, genotype data from the completed 
QC analysis were imputed with IMPUTE2 (Howie et al., 2009) onto the 1000 genomes 
reference panel of 37,426,733 SNPs released in June 2011 
(http://www.1000genomes.org). This version of the 1000 genomes panel contains phased 
haplotypes for 1094 individuals from various ancestral descents including European 
(379), Asian (286), admixed American (181), and African (246). SNPs with r2 > 0.8 were 
considered for future analyses.  
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VII. Study Design 
When studying the commonalities between personality traits and CaD, a unique 
bivariate approach was used. The outcome SNP dosage probability was the independent 
predictor variable and either the ordinal CaD phenotype score or the quantitative 
personality trait was the dependent outcome variable. Outcomes of significance from 
both studies for each SNP (p-values) were combined mathematically via meta-analysis 
and determined to be the bivariate p-value. This method of GWAS was performed with 
outcome variables of each of the five domains of personality trait scores in the discovery 
data set and also with the CaD ordinal trait within the SAGE data set. 
 
VIII. Statistical Methods 
The association of the outcome variable with each SNP was evaluated using a 
linear regression model with the imputed SNP dosage as the predictor variable and the 
phenotype score or trait as the outcome variable. This method of GWAS was performed 
with outcome variables of each of the five domains of personality trait scores in the 
discovery data set and also with the CaD ordinal trait within the SAGE data set. All 
models were adjusted for age, sex, and the first three principal components of ancestry. 
Studies were performed with logistic random effects models embedded within 
generalized estimator equations correcting for related individuals (Zeger et al., 1986).  
Data analyses were performed separately in AAs and EAs and the results were 
combined across data sets and populations by meta-analysis using the inverse variance 
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method in the program METAL (Willer et al., 2010). The total sample size is shown in 
Table 3.  
 
Table 3. Sample Sizes of Individuals Analyzed in Both Data Sets 
AA EA Total 
Male Female Male Female 
Discovery (NEO) 1011 920 881 636 3448 
SAGE (CaD) 643 668 1222 1530 4063 
 
This p-value from the meta-analysis of data across discovery and SAGE datasets within 
an ethnic group was considered as a bivariate measure of significance for the association 
of a SNP for both CaD and a personality trait. Finally, results from all four analyses were 
meta-analyzed. This entire procedure was repeated for each personality domain. Results 
were considered as GWS (p<5.00E-08) based on a standard Bonferroni correction 
accounting for the approximate 500,000 independent SNP tests in the GWAS. This does 
not account for the multiple testing within the five different personality domains and each 
individual domain was considered one set of tests.  
In narrowing down a specific causative area of personality, a correlation analysis 
adjusted for age and sex was performed within the entire discovery data set between CaD 
trait and each of the five domain trait scores of neuroticism, extraversion, openness to 
experience, agreeableness, and conscientiousness. For the five domains in which the 
correlations of CaD and personality were highly significant (p<5.00E-08) among both 
AAs and EAs, further analysis was performed (via the previous GWAS) for the six 
individual facets of that domain.  
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IX. Pathway Analysis 
In order to connect all the individual genes with each other and build a model of 
interactions, pathway analysis was used. This process can build networks of signaling 
pathways, predict downstream effects of disease processes, and predict activation and 
inhibition of upstream transcription factors. This procedure can verify results and map 
out a plan for functional research. Protein products of genes with SNPs of p<1.00E-05 
were collected and analyzed with Ingenuity Pathway Analysis (IPA) (QIAGEN Redwood 
City, www.qiagen.com/ingenuity), which mapped the biological interactions based on 
multiple pathways databases such as KEGG and BioCarta.  
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RESULTS 
I. NEO Domain and CaD GWAS  
Selected results of SNPs from meta-analyses of a personality trait domain with 
CaD are displayed in Tables 4 – 8. SNPs were chosen based on functional relevance or 
significant p-value. Represented in the tables are meta-analyses p-values of all four data 
sets (Meta All). Next, there are two data set meta-analyses across trait or ethnicity for 
personality, CaD, AAs, and EAs. The final four columns display the p-values within each 
of the four individual analysis groups. All SNPs are both reliable (imputation quality / r2 
> 0.80) and common (MAF > 0.05). The global frequencies, frequencies of individual 




Table 4. Top GWAS Results of NEO Domain Neuroticism Meta-Analyzed With Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
2 54,275,162 rs13414393 INT LOC100506338 2.33E-05 9.62E-02 2.44E-05 9.59E-01 2.58E-08 3.05E-01 2.47E-04 1.85E-01 2.52E-05
2 54,301,064 rs6545384 INT LOC100506338 1.35E-06 1.75E-03 2.26E-04 2.68E-01 5.20E-08 4.82E-01 8.70E-05 3.74E-01 1.10E-04
2 54,312,153 rs1058320 . . 3.88E-05 3.05E-02 3.17E-04 9.86E-01 5.28E-08 5.90E-01 1.09E-04 4.95E-01 9.44E-05
2 54,313,836 rs7591194 . . 2.07E-05 2.04E-02 2.61E-04 8.50E-01 4.20E-08 7.41E-01 1.09E-04 4.85E-01 7.66E-05
2 54,314,610 rs7560947 . . 9.96E-06 1.99E-02 1.12E-04 6.34E-01 5.18E-08 7.56E-01 1.13E-04 2.60E-01 9.03E-05
2 54,328,837 rs10207537 . . 4.79E-06 1.10E-02 1.06E-04 5.18E-01 3.73E-08 9.14E-01 7.71E-05 2.51E-01 8.89E-05
2 54,343,108 rs9808326 INT ACYP2 1.80E-05 3.14E-02 1.19E-04 6.78E-01 1.00E-07 6.95E-01 2.27E-04 2.59E-01 9.78E-05
3 131,555,963 rs1606513 INT CPNE4 3.21E-03 2.44E-05 9.05E-01 8.11E-01 2.15E-04 3.38E-01 1.28E-07 4.32E-01 4.92E-01
3 131,556,537 rs12639530 INT CPNE4 2.20E-03 1.76E-05 8.35E-01 6.81E-01 2.13E-04 2.88E-01 1.33E-07 5.20E-01 4.86E-01
3 131,560,408 rs2077634 INT CPNE4 2.35E-03 1.84E-05 8.50E-01 6.80E-01 2.37E-04 2.93E-01 1.35E-07 5.30E-01 5.07E-01
4 157,527,974 rs4691363 . . 6.62E-07 2.18E-07 4.71E-02 5.36E-05 2.10E-03 4.57E-06 8.22E-03 4.30E-01 6.18E-02
4 157,528,080 rs1402780 . . 6.68E-07 2.22E-07 4.70E-02 5.45E-05 2.10E-03 4.68E-06 8.20E-03 4.30E-01 6.17E-02
4 157,528,247 rs939688 . . 7.07E-07 2.17E-07 4.91E-02 5.46E-05 2.20E-03 4.57E-06 8.20E-03 4.34E-01 6.42E-02
4 157,528,765 rs4690868 . . 2.48E-07 1.19E-07 3.26E-02 1.55E-05 2.09E-03 2.23E-06 8.16E-03 2.92E-01 6.16E-02
4 157,528,928 rs4690869 . . 4.47E-07 2.22E-07 3.65E-02 3.30E-05 2.09E-03 4.68E-06 8.20E-03 3.31E-01 6.15E-02
4 157,529,699 rs13129297 . . 4.31E-07 2.11E-07 3.64E-02 3.09E-05 2.11E-03 4.30E-06 8.34E-03 3.30E-01 6.15E-02
4 157,529,838 rs13129704 . . 4.29E-07 2.10E-07 3.64E-02 3.06E-05 2.12E-03 4.25E-06 8.37E-03 3.30E-01 6.15E-02
4 157,530,001 rs10027485 . . 4.27E-07 2.09E-07 3.64E-02 3.05E-05 2.12E-03 4.22E-06 8.39E-03 3.30E-01 6.14E-02
4 157,530,046 rs12711310 . . 4.27E-07 2.09E-07 3.64E-02 3.04E-05 2.12E-03 4.20E-06 8.40E-03 3.30E-01 6.14E-02
4 157,530,060 rs12711311 . . 4.27E-07 2.09E-07 3.64E-02 3.04E-05 2.12E-03 4.20E-06 8.40E-03 3.30E-01 6.14E-02
4 157,530,695 rs4691364 . . 1.58E-07 7.62E-08 2.95E-02 1.93E-05 1.23E-03 3.94E-06 3.75E-03 2.63E-01 6.12E-02




Table 5. Top GWAS Results of NEO Domain Extraversion Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
1 23,785,760 rs7551124 INT ASAP3 1.91E-05 4.38E-02 7.63E-05 4.50E-01 5.38E-07 9.37E-01 1.76E-03 1.99E-01 8.85E-05
1 23,788,994 rs10917383 INT ASAP3 1.87E-05 4.34E-02 7.53E-05 4.49E-01 5.23E-07 9.40E-01 1.75E-03 2.00E-01 8.64E-05
2 127,546,999 rs6716185 . . 4.95E-07 1.04E-04 1.10E-03 3.01E-05 2.42E-03 7.32E-05 1.69E-01 8.02E-02 5.84E-03
2 127,547,766 rs62159603 . . 4.51E-07 9.52E-05 1.09E-03 2.70E-05 2.40E-03 6.53E-05 1.68E-01 7.94E-02 5.83E-03
2 127,549,510 rs62159604 . . 3.89E-07 8.27E-05 1.06E-03 2.34E-05 2.33E-03 5.66E-05 1.64E-01 7.76E-02 5.80E-03
2 207,954,584 rs114657667 INT KLF7 4.51E-01 1.91E-01 2.57E-02 3.45E-03 1.22E-01 4.30E-01 2.79E-01 2.75E-08 2.61E-01
5 1,228,323 rs58933348 INT SLC6A18 3.13E-05 1.19E-05 1.04E-01 3.83E-04 1.52E-02 1.58E-05 8.32E-02 7.30E-01 8.22E-02
5 2,655,779 rs16870234 . . 4.71E-03 2.87E-01 4.20E-03 8.75E-04 3.96E-01 5.06E-01 3.93E-01 9.60E-06 6.72E-01
5 7,519,762 rs6867567 INT ADCY2 4.27E-01 2.23E-02 3.05E-01 3.85E-01 7.01E-02 3.46E-01 6.52E-06 8.24E-01 2.75E-01
5 113,327,356 rs296496 . . 1.70E-01 8.95E-01 4.71E-02 1.65E-02 7.87E-01 5.64E-01 6.51E-01 7.79E-06 5.01E-01
5 118,349,058 rs17144869 . . 2.26E-04 1.65E-01 1.88E-04 7.45E-01 4.05E-06 7.67E-01 1.52E-02 3.84E-01 8.23E-05
5 118,495,671 rs11742202 INT DMXL1 1.20E-03 5.05E-01 1.51E-04 7.02E-01 3.65E-06 2.55E-01 2.21E-02 4.36E-01 4.75E-05
5 147,038,335 rs13162410 INT LOC153469 3.84E-05 5.80E-01 3.64E-07 1.82E-02 6.66E-04 6.02E-01 8.05E-01 2.07E-03 5.01E-05
5 147,038,335 rs13162410 INT LOC153469 3.84E-05 5.80E-01 3.64E-07 1.82E-02 6.66E-04 6.02E-01 8.05E-01 2.07E-03 5.01E-05
5 147,054,820 rs12653567 . . 2.73E-03 6.73E-01 8.06E-06 4.35E-01 9.88E-04 4.73E-01 8.63E-01 3.58E-02 7.05E-05
7 84,952,631 rs12534830 . near SEMA3D 1.49E-05 2.63E-01 1.19E-06 9.02E-01 1.73E-08 1.36E-01 7.56E-04 4.52E-02 6.20E-06
7 84,995,484 rs12536813 . near SEMA3D 4.29E-05 3.36E-01 2.93E-06 8.45E-01 2.18E-08 1.25E-01 1.46E-03 1.20E-01 4.07E-06
8 27,325,473 rs747111 INT CHRNA2 3.54E-04 3.07E-04 1.26E-01 2.58E-07 8.04E-01 7.61E-03 1.51E-02 1.16E-06 1.35E-01
9 111,941,854 rs885505 INT EPB41L4B 7.69E-04 4.44E-05 4.17E-01 4.27E-05 3.70E-01 6.11E-06 2.92E-01 3.44E-01 7.39E-01
9 111,942,454 rs10759333 INT EPB41L4B 1.73E-03 1.51E-05 7.85E-01 2.27E-05 6.43E-01 5.69E-06 1.60E-01 2.48E-01 6.41E-01
9 111,943,009 rs10816778 INT EPB41L4B 1.87E-03 1.53E-05 8.07E-01 2.31E-05 6.63E-01 5.50E-06 1.64E-01 2.54E-01 6.24E-01
9 111,943,210 rs10114938 INT EPB41L4B 2.59E-02 1.01E-03 1.00E+00 9.34E-05 6.52E-01 9.10E-06 9.59E-01 4.48E-01 6.01E-01
9 111,943,276 rs7031103 INT EPB41L4B 2.05E-03 1.48E-05 8.41E-01 2.85E-05 6.59E-01 5.33E-06 1.63E-01 2.90E-01 6.27E-01
10 125,509,947 rs2362675 INT CPXM2 3.47E-04 1.29E-01 5.27E-04 8.06E-01 7.10E-07 8.37E-01 4.00E-02 5.25E-01 3.30E-06
10 125,510,357 rs10736932 INT CPXM2 2.49E-04 1.16E-01 4.10E-04 8.36E-01 4.67E-07 8.43E-01 3.19E-02 5.72E-01 2.82E-06
10 125,524,323 rs1219743 INT CPXM2 1.16E-03 7.70E-01 3.37E-05 4.81E-01 8.52E-07 3.40E-01 1.29E-01 9.60E-01 5.60E-07
14 32,336,134 rs1959074 . . 3.19E-03 3.44E-01 1.70E-03 1.30E-05 9.11E-01 2.74E-01 8.48E-01 3.21E-08 9.97E-01




AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 




Table 6. Top GWAS Results of NEO Domain Openness to Experience Meta-analyzed with Results from GWAS of CaD.  
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
1 203,378,005 rs10920639 . . 8.93E-03 7.88E-04 6.43E-01 5.51E-01 3.19E-03 3.21E-01 8.11E-05 7.89E-01 4.55E-01
1 203,380,765 rs10753942 . . 2.25E-03 2.02E-05 8.21E-01 1.14E-01 7.49E-03 3.94E-02 4.08E-05 9.89E-01 7.76E-01
1 203,383,069 rs137956967 . . 3.08E-03 3.47E-05 8.34E-01 1.78E-01 5.93E-03 3.95E-02 8.89E-05 7.04E-01 6.05E-01
1 203,383,898 rs10920644 . . 9.70E-03 2.17E-03 4.89E-01 3.54E-01 8.72E-03 5.72E-01 6.75E-05 4.40E-01 7.58E-01
1 203,384,102 rs2365601 . . 2.42E-03 2.10E-05 8.38E-01 1.52E-01 5.54E-03 2.59E-02 9.64E-05 6.53E-01 5.76E-01
1 203,386,034 rs141929587 . . 9.05E-04 1.28E-05 6.23E-01 1.35E-01 1.94E-03 3.20E-02 3.18E-05 8.02E-01 4.41E-01
1 203,387,513 rs16851575 . . 2.98E-03 2.33E-05 8.88E-01 1.30E-01 8.77E-03 3.54E-02 6.21E-05 8.62E-01 7.71E-01
1 203,390,302 rs4638182 . . 3.16E-04 1.43E-07 9.60E-01 2.11E-02 5.64E-03 7.59E-04 3.58E-05 6.46E-01 7.05E-01
1 203,390,784 rs4971224 . . 4.59E-04 2.23E-07 9.95E-01 2.95E-02 5.95E-03 1.04E-03 4.00E-05 5.78E-01 7.07E-01
2 133,372,800 rs67992216 INT GPR39 5.95E-02 5.12E-01 5.01E-02 5.73E-07 6.33E-02 7.49E-03 4.24E-02 3.89E-06 4.20E-01
2 206,082,907 rs7564553 INT PARD3B 8.47E-05 1.35E-02 2.15E-03 8.51E-01 4.41E-07 4.19E-01 4.91E-03 4.93E-01 2.65E-05
2 206,087,701 rs6435277 INT PARD3B 1.84E-04 3.65E-02 1.59E-03 9.38E-01 9.95E-07 4.72E-01 1.92E-02 4.53E-01 1.33E-05
2 207,954,584 rs114657667 INT KLF7 1.30E-01 8.51E-01 2.57E-02 5.84E-03 6.93E-01 3.14E-01 3.94E-01 2.75E-08 2.61E-01
3 22,017,246 rs13097046 INT LOC100505836 3.02E-03 6.47E-05 7.25E-01 2.21E-01 4.15E-03 7.56E-02 5.87E-05 8.17E-01 5.57E-01
3 22,017,747 rs56152519 INT LOC100505836 8.60E-03 2.25E-06 4.33E-01 2.34E-02 1.31E-01 7.94E-03 3.55E-05 7.31E-01 2.34E-01
3 22,018,756 rs62248370 INT LOC100505836 1.18E-02 1.33E-05 5.55E-01 3.33E-02 1.38E-01 2.92E-02 4.03E-05 4.84E-01 2.30E-01
3 22,019,084 rs34565874 INT LOC100505836 3.43E-02 4.88E-05 3.88E-01 1.23E-01 1.44E-01 8.18E-02 3.19E-05 7.52E-01 2.05E-01
3 22,019,365 rs56006694 INT LOC100505836 2.94E-02 6.51E-05 4.73E-01 9.85E-02 1.47E-01 9.44E-02 3.57E-05 5.70E-01 2.06E-01
3 22,019,860 rs17644807 INT LOC100505836 3.01E-02 6.60E-05 4.67E-01 9.89E-02 1.50E-01 9.44E-02 3.65E-05 5.72E-01 2.03E-01
4 110,160,079 rs6533422 INT COL25A1 4.97E-03 5.32E-04 5.30E-01 7.22E-01 6.35E-04 2.56E-01 8.11E-05 4.13E-01 1.84E-01
4 110,167,627 rs978633 INT COL25A1 2.27E-02 5.31E-06 2.74E-01 5.08E-01 1.44E-02 1.24E-02 5.30E-05 4.61E-02 9.63E-01
5 147,038,335 rs13162410 INT LOC153469 1.10E-04 8.52E-01 3.64E-07 2.20E-03 1.38E-02 1.53E-01 1.83E-01 2.07E-03 5.01E-05
7 17,133,514 rs7801891 . 2.04E-02 1.51E-03 8.19E-01 4.91E-08 9.33E-02 1.05E-07 2.24E-01 3.37E-02 2.35E-01
7 84,952,631 rs12534830 . . 7.44E-06 1.80E-01 1.19E-06 2.51E-01 7.70E-07 8.71E-01 2.75E-02 4.52E-02 6.20E-06
8 18,199,560 rs34290224 . . 1.08E-01 2.01E-02 9.66E-01 7.65E-08 1.07E-02 7.29E-05 3.32E-01 2.74E-04 1.39E-02
11 95,213,173 rs2000798 . . 1.25E-03 2.62E-01 7.92E-04 3.06E-06 8.30E-01 1.40E-01 9.79E-01 2.89E-08 8.04E-01
11 95,215,799 rs6483425 . . 1.26E-04 1.49E-01 1.02E-04 3.19E-07 5.27E-01 4.14E-02 8.99E-01 2.65E-08 3.78E-01
14 32,336,134 rs1959074 . . 7.88E-02 4.17E-01 1.70E-03 1.76E-02 7.93E-01 1.39E-01 6.56E-01 3.21E-08 9.97E-01
15 40,155,759 rs8027511 INT GPR176 3.65E-05 6.51E-01 2.03E-07 2.27E-01 9.68E-06 4.68E-01 8.91E-01 3.09E-01 2.00E-08




AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 





Table 7. Top GWAS Results of NEO Domain Agreeableness Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
2 207,954,584 rs114657667 INT KLF7 5.71E-02 7.00E-01 2.57E-02 2.42E-04 5.00E-01 8.59E-01 7.03E-01 2.75E-08 2.61E-01
5 147,038,335 rs13162410 INT LOC153469 2.42E-05 4.78E-01 3.64E-07 1.67E-03 4.22E-03 1.25E-01 5.08E-01 2.07E-03 5.01E-05
5 175,256,368 rs17767831 INT CPLX2 2.03E-04 9.37E-05 1.46E-01 2.29E-02 3.23E-03 1.73E-01 1.35E-05 5.44E-02 6.62E-01
5 175,268,350 rs6887312 INT CPLX2 4.71E-04 9.09E-06 5.05E-01 3.93E-02 4.49E-03 7.59E-02 2.76E-06 2.77E-01 9.53E-01
7 75,611,149 rs10954732 INT POR 5.55E-06 1.94E-01 6.36E-07 3.78E-02 2.49E-05 3.03E-01 4.26E-01 4.38E-02 3.17E-06
7 150,652,419 rs876088 INT KCNH2 1.55E-03 9.84E-04 2.05E-01 9.69E-08 6.54E-01 2.15E-06 7.05E-01 8.43E-03 7.81E-01
10 16,588,144 rs8181375 . . 1.00E-04 7.46E-07 4.65E-01 1.10E-03 2.05E-02 1.18E-05 1.18E-02 8.53E-01 3.10E-01
10 49,774,924 rs75482917 INT ARHGAP22 3.70E-04 9.08E-03 1.48E-02 3.71E-07 7.69E-01 6.94E-05 5.79E-01 1.55E-03 4.37E-01
11 11,410,281 rs10765845 INT GALNTL4 1.13E-02 7.32E-01 1.71E-04 3.43E-01 1.13E-02 6.19E-01 2.81E-01 3.75E-01 7.65E-05
11 11,410,851 rs7945241 INT GALNTL4 5.82E-03 6.99E-01 4.03E-05 2.87E-01 6.34E-03 5.78E-01 2.26E-01 3.17E-01 1.72E-05
11 11,412,180 rs4910331 INT GALNTL4 1.13E-02 7.51E-01 1.86E-04 2.61E-01 1.72E-02 3.55E-01 1.28E-01 5.20E-01 4.17E-05
11 11,627,222 rs7932013 INT GALNTL4 2.76E-03 4.49E-06 8.76E-01 3.71E-02 3.12E-02 6.53E-05 1.59E-02 1.17E-01 3.72E-01
12 82,141,237 rs2464735 INT PPFIA2 4.04E-03 9.03E-01 5.79E-05 1.68E-01 5.27E-07 1.31E-02 8.89E-03 4.00E-01 1.67E-05
14 32,336,134 rs1959074 . . 1.42E-01 2.15E-01 1.70E-03 3.30E-03 5.40E-01 4.54E-01 3.06E-01 3.21E-08 9.97E-01




Table 8. Top GWAS Results Of NEO Domain Conscientiousness Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
2 133,372,800 rs67992216 INT GPR39 3.38E-02 3.15E-01 5.01E-02 1.45E-07 7.71E-02 2.62E-03 6.02E-02 3.89E-06 4.20E-01
2 207,954,584 rs114657667 INT KLF7 2.12E-01 5.61E-01 2.57E-02 2.83E-03 3.43E-01 4.78E-01 9.40E-01 2.75E-08 2.61E-01
3 24,793,811 rs4241533 . . 1.21E-03 4.21E-07 7.94E-01 2.68E-02 1.82E-02 3.32E-05 3.23E-03 1.20E-01 4.50E-01
3 24,794,334 rs9856030 . . 1.11E-03 4.61E-07 8.32E-01 2.50E-02 1.78E-02 3.72E-05 3.20E-03 1.39E-01 4.45E-01
3 24,795,211 rs6791127 . . 1.10E-03 4.51E-07 8.32E-01 2.52E-02 1.75E-02 3.65E-05 3.18E-03 1.36E-01 4.41E-01
3 24,795,619 rs6776123 . . 1.19E-03 5.23E-07 8.30E-01 2.73E-02 1.75E-02 4.29E-05 3.19E-03 1.35E-01 4.41E-01
3 24,797,525 rs7642276 . . 9.41E-04 3.22E-07 8.33E-01 2.11E-02 1.74E-02 2.45E-05 3.24E-03 1.35E-01 4.38E-01
3 24,799,312 rs9882619 . . 5.77E-04 1.24E-07 8.48E-01 1.65E-02 1.32E-02 1.36E-05 2.18E-03 1.31E-01 4.18E-01
3 24,802,235 rs6550899 . . 5.83E-04 1.53E-07 8.73E-01 1.82E-02 1.23E-02 1.58E-05 2.34E-03 1.27E-01 3.90E-01
3 24,821,446 rs7621115 . . 9.69E-04 3.49E-07 8.36E-01 2.64E-02 1.46E-02 2.36E-05 3.60E-03 1.01E-01 3.79E-01
3 24,833,960 rs5002695 . . 5.03E-04 2.21E-07 9.66E-01 1.26E-02 1.46E-02 1.26E-05 3.93E-03 1.68E-01 3.68E-01
3 24,833,960 rs5002695 . . 5.03E-04 2.21E-07 9.66E-01 1.26E-02 1.46E-02 1.26E-05 3.93E-03 1.68E-01 3.68E-01
3 24,834,316 rs6763459 . . 5.30E-05 7.17E-08 5.94E-01 1.39E-03 1.00E-02 5.44E-06 2.78E-03 6.24E-01 3.24E-01
3 24,834,316 rs6763459 . . 5.30E-05 7.17E-08 5.94E-01 1.39E-03 1.00E-02 5.44E-06 2.78E-03 6.24E-01 3.24E-01
3 24,834,378 rs4361227 . . 1.39E-04 2.12E-05 2.06E-01 1.16E-03 2.61E-02 4.59E-05 7.01E-02 8.72E-01 1.54E-01
5 147,038,335 rs13162410 INT LOC153469 5.21E-05 6.53E-01 3.64E-07 1.29E-02 1.38E-03 4.93E-01 9.24E-01 2.07E-03 5.01E-05
7 75,611,149 rs10954732 INT POR 5.77E-04 7.45E-01 6.36E-07 1.52E-01 9.06E-04 8.46E-01 4.78E-01 4.38E-02 3.17E-06
8 20,095,572 rs11204103 . . 2.32E-03 1.33E-01 5.83E-03 2.49E-01 4.52E-07 5.62E-01 3.50E-03 2.67E-01 3.85E-05
10 49,775,175 rs935295 INT ARHGAP22 5.53E-03 2.05E-01 9.17E-03 5.17E-07 4.87E-01 7.67E-05 1.07E-02 1.97E-03 3.03E-01
10 125,524,323 rs1219743 INT CPXM2 4.68E-05 1.32E-01 3.37E-05 9.21E-01 1.07E-07 9.31E-01 2.97E-02 9.60E-01 5.60E-07
12 13,911,777 rs10492136 INT GRIN2B 4.03E-04 3.39E-05 3.22E-01 4.12E-05 2.63E-01 3.58E-06 3.07E-01 4.10E-01 5.25E-01
12 13,911,933 rs73300369 INT GRIN2B 1.08E-03 1.23E-04 3.65E-01 1.86E-04 2.81E-01 1.81E-05 3.41E-01 5.00E-01 5.25E-01
12 13,914,816 rs7316902 INT GRIN2B 1.23E-04 1.26E-06 4.49E-01 1.30E-05 1.96E-01 1.77E-06 5.55E-02 2.90E-01 8.50E-01
12 13,919,214 rs2284416 INT GRIN2B 3.22E-04 9.34E-06 4.19E-01 5.32E-05 2.11E-01 1.66E-05 6.83E-02 2.59E-01 8.39E-01
14 32,336,134 rs1959074 . . 9.06E-03 6.56E-01 1.70E-03 1.79E-04 8.44E-01 7.65E-01 7.38E-01 3.21E-08 9.97E-01
15 40,155,759 rs8027511 INT GPR176 3.08E-04 7.53E-01 2.03E-07 6.65E-01 1.03E-05 7.81E-01 8.72E-01 3.09E-01 2.00E-08




Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
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II. NEO Domain and CaD Pathway Analysis  
All SNPs within genes (p<1.00E-05) from the five NEO domain analyses were 
selected, which summed to approximately 150 independent genes. This list of genes was 
submitted to IPA to determine regulatory links between proteins using multiple pathway 
databases (e.g. KEGG, BioCarta, etc.). Figure 1 represents a collection of these 
previously elucidated pathways from a variety of different databases. The representative 
network contains the highest number of genes (23 molecules) from the list of 
approximately 150 top hits and this network is called “Inflammatory Disease, Ophthalmic 




Figure 1. Pathway Analysis Results of Genes within NEO Domains and CaD Meta-analyses. 
 
Important genes in this pathway include the ion transport proteins KCNH2 and 
SLCO3A1. Akt/PKB plays a central role and is regulated by PI3K, which interacts with 
PIK3IP1. In addition to the individual gene analysis, associated canonical pathways 




III. NEO Domain and CaD Correlation Analysis  
Correlation coefficients of the ordinal measure of CaD and NEO domain scores 
were determined to direct further genetic association analysis of individual domain(s). As 
shown in Table 9, the correlations with the neuroticism domain were very significant, 
several orders of magnitude more significant than those with other NEO domains, and 
comparable in both AAs and EAs.  
 
Table 9. Correlation Coefficients and p-values of NEO domains and CaD ordinal 7 trait 
scores within discovery data set. 
 
Openness Conscientiousness Extraversion Agreeableness Neuroticism 
AA estimate -0.030 -0.130 -0.063 -0.069 0.178 
  p-value 1.93E-01 8.81E-09 5.60E-03 2.28E-03 3.11E-15 
EA estimate 0.041 -0.088 -0.039 -0.028 0.164 
  p-value 1.09E-01 6.32E-04 1.33E-01 2.84E-01 1.45E-10 
  
 
IV. NEO Facet and CaD GWAS  
Based on the correlation analysis, association of CaD with individual facets 
within the neuroticism domain was evaluated to see if a more precise aspect of 
personality has shared genetic determinants with CaD. This was performed with GWAS 




Table 10. Top GWAS Results of Neuroticism Facet Anxiety Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
3 131,536,917 rs16837870 INT CPNE4 9.02E-02 3.07E-03 6.72E-01 3.26E-01 1.91E-03 7.85E-01 1.83E-06 2.25E-01 7.47E-01
3 131,537,570 rs3914307 INT CPNE4 4.87E-02 1.44E-03 7.98E-01 5.84E-01 1.99E-03 9.71E-01 1.91E-06 3.65E-01 7.53E-01
3 131,537,647 rs4092640 INT CPNE4 8.25E-02 2.28E-03 6.53E-01 3.69E-01 2.03E-03 8.92E-01 2.00E-06 2.12E-01 7.53E-01
3 131,539,334 rs1026747 INT CPNE4 8.53E-02 2.29E-03 6.38E-01 3.78E-01 2.28E-03 8.95E-01 2.07E-06 2.20E-01 7.83E-01
3 131,541,210 rs16837878 INT CPNE4 5.39E-02 1.63E-03 7.78E-01 5.94E-01 2.52E-03 9.73E-01 2.46E-06 3.79E-01 7.91E-01
3 131,543,767 rs6439319 INT CPNE4 6.79E-02 1.97E-03 7.12E-01 4.02E-01 1.62E-03 8.78E-01 1.30E-06 2.58E-01 7.40E-01
3 131,544,079 rs7648064 INT CPNE4 5.48E-02 1.07E-03 6.88E-01 4.90E-01 1.64E-03 9.46E-01 1.21E-06 2.43E-01 7.51E-01
3 131,546,194 rs1464068 INT CPNE4 4.19E-02 1.25E-03 8.36E-01 6.03E-01 1.62E-03 9.97E-01 1.16E-06 4.11E-01 7.52E-01
3 131,546,747 rs67051425 INT CPNE4 7.25E-02 1.97E-03 6.83E-01 3.80E-01 1.65E-03 8.67E-01 1.21E-06 2.39E-01 7.52E-01
3 131,551,585 rs61202912 INT CPNE4 7.22E-02 1.94E-03 6.81E-01 3.83E-01 1.66E-03 8.73E-01 1.21E-06 2.39E-01 7.54E-01
3 131,555,963 rs1606513 INT CPNE4 2.05E-02 1.00E-03 9.05E-01 7.07E-01 6.72E-04 8.72E-01 1.76E-06 4.32E-01 4.92E-01
3 131,556,537 rs12639530 INT CPNE4 1.32E-02 5.97E-04 8.35E-01 8.94E-01 6.63E-04 7.21E-01 1.82E-06 5.20E-01 4.86E-01
3 131,560,156 rs750048 INT CPNE4 7.61E-02 2.12E-03 6.76E-01 3.75E-01 1.77E-03 8.57E-01 1.33E-06 2.40E-01 7.62E-01
3 131,560,408 rs2077634 INT CPNE4 1.44E-02 6.56E-04 8.50E-01 8.91E-01 7.62E-04 7.34E-01 2.00E-06 5.30E-01 5.07E-01
3 131,562,955 rs59025993 INT CPNE4 5.66E-02 2.02E-03 8.01E-01 5.57E-01 2.36E-03 8.68E-01 1.29E-06 4.70E-01 8.47E-01
3 131,563,467 rs7632654 INT CPNE4 8.96E-02 2.67E-03 6.47E-01 3.60E-01 2.30E-03 7.84E-01 1.32E-06 2.69E-01 8.37E-01
3 131,563,872 rs6763315 INT CPNE4 9.05E-02 2.68E-03 6.43E-01 3.60E-01 2.35E-03 7.84E-01 1.33E-06 2.69E-01 8.42E-01
3 131,563,898 rs6787747 INT CPNE4 7.33E-02 4.95E-03 8.78E-01 3.45E-01 1.38E-03 5.65E-01 1.03E-06 4.32E-01 7.22E-01
3 131,565,157 rs67078110 INT CPNE4 8.99E-02 2.68E-03 6.46E-01 3.60E-01 2.31E-03 7.83E-01 1.32E-06 2.69E-01 8.38E-01
3 131,565,742 rs66506820 INT CPNE4 5.35E-02 1.93E-03 8.17E-01 5.73E-01 2.27E-03 8.80E-01 1.27E-06 4.82E-01 8.38E-01
3 131,568,832 rs4854626 INT CPNE4 6.87E-02 2.40E-03 7.48E-01 4.84E-01 2.49E-03 8.19E-01 1.33E-06 4.11E-01 8.60E-01
3 131,569,008 rs4854627 INT CPNE4 5.60E-02 1.70E-03 7.70E-01 5.88E-01 2.64E-03 9.97E-01 2.27E-06 3.92E-01 8.14E-01
22 46,189,190 rs136002 INT ATXN10 3.47E-04 2.19E-05 3.40E-01 6.71E-05 2.04E-01 2.16E-06 2.92E-01 6.04E-01 4.23E-01




Table 11. Top GWAS Results of Neuroticism Facet Depression Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
3 2,365,990 rs1145041 INT CNTN4 3.46E-03 3.23E-05 8.84E-01 4.81E-01 1.10E-03 1.66E-01 2.56E-06 5.67E-01 5.67E-01
3 2,382,995 rs1627079 INT CNTN4 1.39E-03 4.32E-05 5.63E-01 3.99E-01 4.55E-04 2.01E-01 2.32E-06 8.21E-01 3.90E-01
3 2,384,639 rs1666326 INT CNTN4 1.25E-03 8.74E-06 7.71E-01 3.17E-01 6.57E-04 6.00E-02 4.62E-06 4.79E-01 4.00E-01
3 2,385,167 rs1720179 INT CNTN4 1.26E-03 8.92E-06 7.69E-01 3.17E-01 6.59E-04 6.01E-02 4.75E-06 4.79E-01 3.98E-01
3 2,385,295 rs1685491 INT CNTN4 1.39E-03 4.21E-05 5.66E-01 3.95E-01 4.66E-04 1.98E-01 2.33E-06 8.23E-01 3.94E-01
3 2,385,305 rs4685515 INT CNTN4 1.25E-02 3.30E-04 9.31E-01 8.70E-01 1.53E-03 4.19E-01 6.75E-06 4.69E-01 5.45E-01
3 2,385,988 rs12639121 INT CNTN4 1.17E-02 3.24E-04 9.07E-01 8.59E-01 1.42E-03 4.30E-01 5.90E-06 4.98E-01 5.42E-01
3 2,386,340 rs1685492 INT CNTN4 1.40E-03 4.22E-05 5.67E-01 3.94E-01 4.72E-04 1.98E-01 2.34E-06 8.24E-01 3.96E-01
3 2,386,988 rs1554562 INT CNTN4 1.48E-03 1.32E-05 7.57E-01 3.61E-01 6.23E-04 8.09E-02 4.25E-06 4.95E-01 3.97E-01
3 2,387,439 rs1566382 INT CNTN4 1.47E-03 3.85E-05 5.95E-01 4.05E-01 4.81E-04 1.88E-01 2.35E-06 7.74E-01 3.99E-01
3 2,387,692 rs3856836 INT CNTN4 1.26E-02 2.21E-04 9.93E-01 8.50E-01 1.66E-03 3.99E-01 3.90E-06 4.68E-01 6.24E-01
3 2,387,815 rs1666329 INT CNTN4 1.42E-03 4.24E-05 5.70E-01 3.94E-01 4.82E-04 1.98E-01 2.36E-06 8.24E-01 3.99E-01
3 2,387,835 rs3856838 INT CNTN4 3.55E-03 9.60E-05 7.11E-01 4.44E-01 1.37E-03 2.17E-01 7.21E-06 7.68E-01 5.13E-01
3 2,388,521 rs1617892 INT CNTN4 1.02E-03 2.96E-05 5.35E-01 3.99E-01 2.91E-04 2.00E-01 1.23E-06 8.19E-01 3.62E-01
3 2,389,325 rs2728517 INT CNTN4 1.78E-04 2.79E-06 4.36E-01 1.07E-01 3.64E-04 3.89E-02 2.20E-06 9.75E-01 3.55E-01
3 2,390,612 rs1685495 INT CNTN4 1.50E-03 3.96E-05 5.96E-01 3.96E-01 5.19E-04 1.85E-01 2.59E-06 7.85E-01 4.05E-01
3 2,391,098 rs4684343 INT CNTN4 9.47E-03 1.93E-04 9.26E-01 7.83E-01 1.37E-03 3.50E-01 4.98E-06 4.83E-01 5.50E-01
3 2,392,644 rs968057 INT CNTN4 3.43E-04 1.95E-05 3.50E-01 1.29E-01 6.10E-04 1.17E-01 3.01E-06 6.29E-01 4.23E-01
3 2,392,718 rs4685517 INT CNTN4 2.83E-04 3.10E-06 5.22E-01 8.90E-02 8.56E-04 2.62E-02 6.10E-06 9.81E-01 4.27E-01
3 3,655,219 rs9868273 . . 1.11E-02 3.18E-03 4.63E-01 4.42E-01 6.98E-03 8.62E-01 3.44E-06 1.56E-01 9.31E-01
3 3,655,838 rs766219 . . 1.32E-02 2.04E-03 5.98E-01 3.11E-01 1.62E-02 9.55E-01 2.43E-06 9.65E-02 6.13E-01
4 21,367,902 rs1390259 INT KCNIP4 2.34E-01 9.89E-03 4.49E-01 6.95E-01 2.16E-01 5.61E-01 5.49E-06 1.86E-01 6.67E-02
4 21,368,339 rs2323001 INT KCNIP4 4.44E-01 1.08E-02 1.91E-01 7.05E-01 4.93E-01 5.39E-01 5.72E-06 1.80E-01 1.19E-02
4 21,377,097 rs1994983 INT KCNIP4 1.93E-01 8.18E-04 1.90E-01 2.75E-01 4.37E-01 6.73E-01 4.89E-06 2.28E-01 1.53E-02




Table 12. Top GWAS Results of Neuroticism Facet Hostility Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
5 6,605,271 rs506416 INT NSUN2 1.63E-05 1.84E-07 2.90E-01 5.55E-04 6.75E-03 1.69E-05 2.63E-03 8.35E-01 2.54E-01
5 6,608,534 rs502272 INT NSUN2 2.13E-05 1.91E-07 3.26E-01 6.51E-04 7.65E-03 1.75E-05 2.64E-03 8.81E-01 2.76E-01




Table 13. Top GWAS Results of Neuroticism Facet Impulsiveness Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
6 118,554,463 rs9489325 INT SLC35F1 2.94E-03 3.98E-06 8.37E-01 5.38E-04 3.53E-01 6.10E-06 6.42E-02 9.63E-01 8.28E-01
6 118,555,555 rs928599 INT SLC35F1 3.98E-03 4.24E-06 7.48E-01 8.67E-04 3.59E-01 6.16E-06 6.67E-02 8.03E-01 8.27E-01
6 118,555,615 rs928598 INT SLC35F1 4.06E-03 4.44E-06 7.48E-01 8.96E-04 3.59E-01 6.51E-06 6.69E-02 8.03E-01 8.27E-01
12 81,927,644 rs7304553 INT PPFIA2 1.02E-02 9.66E-07 3.08E-01 1.82E-02 1.77E-01 6.70E-05 3.89E-03 2.61E-01 6.43E-01
12 81,927,864 rs7315394 INT PPFIA2 8.63E-03 9.78E-07 3.47E-01 1.47E-02 1.75E-01 6.79E-05 3.89E-03 3.19E-01 6.50E-01
12 81,944,088 rs17008693 INT PPFIA2 4.07E-03 2.54E-07 3.99E-01 6.41E-03 1.51E-01 3.93E-05 1.73E-03 4.82E-01 5.90E-01
12 81,948,660 rs17008707 INT PPFIA2 4.16E-03 1.65E-07 3.54E-01 6.87E-03 1.48E-01 2.56E-05 1.67E-03 3.91E-01 5.94E-01
12 81,953,738 rs74106644 INT PPFIA2 3.76E-03 2.19E-07 4.04E-01 6.23E-03 1.45E-01 3.64E-05 1.61E-03 4.78E-01 6.00E-01
12 81,956,398 rs12424207 INT PPFIA2 7.65E-03 2.01E-07 2.45E-01 1.37E-02 1.64E-01 9.29E-05 6.08E-04 3.85E-01 4.16E-01
12 81,960,411 rs17008729 INT PPFIA2 3.70E-03 1.42E-07 3.67E-01 5.95E-03 1.46E-01 1.99E-05 1.80E-03 3.94E-01 6.12E-01
12 81,961,143 rs79946680 INT PPFIA2 4.12E-03 2.57E-07 3.98E-01 7.00E-03 1.46E-01 3.84E-05 1.79E-03 4.50E-01 6.13E-01
12 81,964,035 rs74106657 INT PPFIA2 4.13E-03 2.48E-07 3.94E-01 7.35E-03 1.42E-01 3.82E-05 1.74E-03 4.34E-01 6.20E-01
12 81,968,978 rs74106658 INT PPFIA2 4.38E-03 2.44E-07 3.78E-01 8.34E-03 1.39E-01 4.11E-05 1.60E-03 4.07E-01 6.18E-01
12 81,970,885 rs1955385 INT PPFIA2 2.84E-03 2.06E-07 4.68E-01 8.90E-03 9.31E-02 4.76E-05 1.19E-03 4.11E-01 7.53E-01
12 81,973,345 rs74106663 INT PPFIA2 4.29E-03 2.23E-07 3.75E-01 8.59E-03 1.34E-01 4.05E-05 1.49E-03 3.96E-01 6.22E-01
12 82,003,495 rs1955383 INT PPFIA2 5.66E-03 9.26E-08 2.47E-01 1.37E-02 1.28E-01 2.09E-05 1.15E-03 1.98E-01 6.04E-01
15 47,895,543 rs1224671 INT SEMA6D 2.50E-06 3.37E-06 3.39E-02 1.41E-04 3.42E-03 2.31E-06 9.38E-02 8.00E-01 1.63E-02




Table 14. Top GWAS Results of Neuroticism Facet Self-consciousness Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
3 131,536,441 rs61564665 INT CPNE4 5.64E-03 2.07E-04 7.30E-01 4.65E-01 2.40E-03 3.30E-01 6.95E-06 9.73E-01 6.58E-01
3 131,536,917 rs16837870 INT CPNE4 4.52E-02 6.35E-04 6.72E-01 6.22E-01 2.03E-03 7.18E-01 2.11E-06 2.25E-01 7.47E-01
3 131,537,570 rs3914307 INT CPNE4 2.28E-02 2.76E-04 7.98E-01 9.46E-01 2.08E-03 5.10E-01 2.14E-06 3.65E-01 7.53E-01
3 131,537,647 rs4092640 INT CPNE4 3.82E-02 3.88E-04 6.53E-01 7.07E-01 2.09E-03 5.88E-01 2.16E-06 2.12E-01 7.53E-01
3 131,539,334 rs1026747 INT CPNE4 4.05E-02 4.09E-04 6.38E-01 7.15E-01 2.40E-03 5.91E-01 2.34E-06 2.20E-01 7.83E-01
3 131,541,210 rs16837878 INT CPNE4 2.58E-02 3.24E-04 7.78E-01 9.55E-01 2.65E-03 5.15E-01 2.79E-06 3.79E-01 7.91E-01
3 131,543,767 rs6439319 INT CPNE4 3.20E-02 3.63E-04 7.12E-01 7.45E-01 1.76E-03 6.10E-01 1.59E-06 2.58E-01 7.40E-01
3 131,544,079 rs7648064 INT CPNE4 2.93E-02 2.60E-04 6.88E-01 7.97E-01 1.85E-03 5.29E-01 1.62E-06 2.43E-01 7.51E-01
3 131,546,194 rs1464068 INT CPNE4 2.05E-02 2.67E-04 8.36E-01 9.68E-01 1.87E-03 5.32E-01 1.66E-06 4.11E-01 7.52E-01
3 131,546,747 rs67051425 INT CPNE4 3.48E-02 3.72E-04 6.83E-01 7.23E-01 1.88E-03 6.09E-01 1.68E-06 2.39E-01 7.52E-01
3 131,551,585 rs61202912 INT CPNE4 3.52E-02 3.78E-04 6.81E-01 7.23E-01 1.92E-03 6.09E-01 1.73E-06 2.39E-01 7.54E-01
3 131,555,963 rs1606513 INT CPNE4 4.98E-03 5.93E-05 9.05E-01 6.41E-01 9.03E-04 2.11E-01 3.44E-06 4.32E-01 4.92E-01
3 131,556,537 rs12639530 INT CPNE4 3.84E-03 5.32E-05 8.35E-01 5.57E-01 8.89E-04 1.97E-01 3.54E-06 5.20E-01 4.86E-01
3 131,560,156 rs750048 INT CPNE4 3.40E-02 3.40E-04 6.76E-01 7.48E-01 1.99E-03 5.81E-01 1.76E-06 2.40E-01 7.62E-01
3 131,560,408 rs2077634 INT CPNE4 4.01E-03 5.33E-05 8.50E-01 5.52E-01 9.72E-04 1.98E-01 3.49E-06 5.30E-01 5.07E-01
3 131,562,955 rs59025993 INT CPNE4 3.07E-02 5.37E-04 8.01E-01 8.88E-01 2.80E-03 6.80E-01 2.00E-06 4.70E-01 8.47E-01
3 131,563,467 rs7632654 INT CPNE4 3.82E-02 3.75E-04 6.47E-01 7.62E-01 2.58E-03 6.04E-01 1.77E-06 2.69E-01 8.37E-01
3 131,563,872 rs6763315 INT CPNE4 3.86E-02 3.76E-04 6.43E-01 7.61E-01 2.63E-03 6.05E-01 1.77E-06 2.69E-01 8.42E-01
3 131,563,898 rs6787747 INT CPNE4 2.42E-02 4.75E-04 8.78E-01 8.88E-01 1.85E-03 6.42E-01 2.10E-06 4.32E-01 7.22E-01
3 131,565,157 rs67078110 INT CPNE4 3.83E-02 3.75E-04 6.46E-01 7.61E-01 2.59E-03 6.05E-01 1.76E-06 2.69E-01 8.38E-01
3 131,565,742 rs66506820 INT CPNE4 2.23E-02 2.90E-04 8.17E-01 9.83E-01 2.59E-03 5.44E-01 1.76E-06 4.82E-01 8.38E-01
3 131,568,832 rs4854626 INT CPNE4 3.41E-02 5.09E-04 7.48E-01 8.20E-01 2.63E-03 7.02E-01 1.52E-06 4.11E-01 8.60E-01
3 131,569,008 rs4854627 INT CPNE4 1.99E-02 1.74E-04 7.70E-01 8.68E-01 3.25E-03 3.57E-01 3.84E-06 3.92E-01 8.14E-01
5 121,532,284 rs12654712 . . 9.05E-03 1.22E-03 5.69E-01 7.42E-01 1.50E-03 9.96E-01 1.12E-06 6.09E-01 7.34E-01
5 121,534,579 rs17433546 . . 1.13E-02 7.60E-04 7.30E-01 6.43E-01 3.09E-03 7.69E-01 2.09E-06 7.10E-01 8.71E-01
5 121,534,822 rs10519700 . . 1.25E-02 8.53E-03 3.30E-01 9.20E-01 1.25E-03 3.89E-01 7.92E-07 2.29E-01 7.24E-01
5 121,535,090 rs35695438 . . 1.51E-02 2.47E-03 6.07E-01 9.69E-01 1.13E-03 6.92E-01 5.43E-07 6.75E-01 7.37E-01
5 121,535,139 rs1421883 . . 1.02E-02 7.92E-03 2.95E-01 7.88E-01 1.50E-03 4.12E-01 8.27E-07 1.56E-01 7.69E-01




AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 




Table 15. Top GWAS Results of Neuroticism Facet Vulnerability to Stress Meta-analyzed with Results from GWAS of CaD.  
 
Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
1 234,107,275 rs6702481 INT SLC35F3 9.08E-04 8.94E-08 6.78E-01 7.12E-04 1.47E-01 2.74E-05 8.70E-04 8.16E-01 5.06E-01
1 234,107,883 rs11587514 INT SLC35F3 8.02E-04 8.65E-08 7.09E-01 5.74E-04 1.48E-01 2.64E-05 8.72E-04 7.53E-01 5.02E-01
1 234,108,633 rs12567347 INT SLC35F3 9.36E-04 1.30E-07 7.16E-01 7.22E-04 1.49E-01 4.02E-05 8.84E-04 7.39E-01 5.02E-01
1 234,110,769 rs12047995 INT SLC35F3 5.69E-05 3.55E-08 6.93E-01 1.04E-04 5.04E-02 2.10E-05 4.48E-04 3.47E-01 8.66E-01
1 234,116,698 rs4279910 INT SLC35F3 4.10E-04 1.15E-06 7.47E-01 2.54E-04 1.34E-01 2.23E-05 1.08E-02 5.44E-01 9.79E-01
1 234,116,713 rs4362043 INT SLC35F3 4.08E-04 1.16E-06 7.44E-01 2.54E-04 1.34E-01 2.26E-05 1.08E-02 5.42E-01 9.81E-01
3 131,536,289 rs60078694 INT CPNE4 3.84E-02 2.52E-03 9.74E-01 7.39E-01 2.40E-03 9.15E-01 2.95E-06 6.94E-01 7.56E-01
3 131,536,441 rs61564665 INT CPNE4 3.04E-03 6.33E-05 7.30E-01 3.59E-01 1.73E-03 2.24E-01 3.18E-06 9.73E-01 6.58E-01
3 131,536,917 rs16837870 INT CPNE4 5.21E-02 8.79E-04 6.72E-01 5.35E-01 1.83E-03 8.44E-01 1.64E-06 2.25E-01 7.47E-01
3 131,537,570 rs3914307 INT CPNE4 3.28E-02 6.09E-04 7.98E-01 7.54E-01 1.91E-03 7.34E-01 1.72E-06 3.65E-01 7.53E-01
3 131,537,647 rs4092640 INT CPNE4 5.15E-02 7.72E-04 6.53E-01 5.58E-01 1.98E-03 7.87E-01 1.89E-06 2.12E-01 7.53E-01
3 131,539,334 rs1026747 INT CPNE4 5.22E-02 7.37E-04 6.38E-01 5.62E-01 2.07E-03 7.95E-01 1.62E-06 2.20E-01 7.83E-01
3 131,541,210 rs16837878 INT CPNE4 3.57E-02 6.61E-04 7.78E-01 7.63E-01 2.30E-03 7.38E-01 1.97E-06 3.79E-01 7.91E-01
3 131,543,767 rs6439319 INT CPNE4 3.97E-02 5.88E-04 7.12E-01 6.43E-01 1.74E-03 7.40E-01 1.53E-06 2.58E-01 7.40E-01
3 131,544,079 rs7648064 INT CPNE4 3.45E-02 3.75E-04 6.88E-01 7.20E-01 1.82E-03 6.19E-01 1.57E-06 2.43E-01 7.51E-01
3 131,546,194 rs1464068 INT CPNE4 2.75E-02 5.05E-04 8.36E-01 8.18E-01 1.78E-03 7.05E-01 1.46E-06 4.11E-01 7.52E-01
3 131,546,747 rs67051425 INT CPNE4 4.42E-02 6.42E-04 6.83E-01 6.09E-01 1.85E-03 7.58E-01 1.60E-06 2.39E-01 7.52E-01
3 131,551,585 rs61202912 INT CPNE4 4.44E-02 6.42E-04 6.81E-01 6.13E-01 1.89E-03 7.53E-01 1.66E-06 2.39E-01 7.54E-01
3 131,555,963 rs1606513 INT CPNE4 5.40E-03 6.98E-05 9.05E-01 9.56E-01 2.70E-04 4.72E-01 2.17E-07 4.32E-01 4.92E-01
3 131,556,537 rs12639530 INT CPNE4 3.07E-03 3.40E-05 8.35E-01 7.51E-01 2.60E-04 3.47E-01 2.13E-07 5.20E-01 4.86E-01
3 131,560,156 rs750048 INT CPNE4 4.74E-02 7.24E-04 6.76E-01 5.94E-01 1.97E-03 7.81E-01 1.73E-06 2.40E-01 7.62E-01
3 131,560,408 rs2077634 INT CPNE4 3.28E-03 3.57E-05 8.50E-01 7.49E-01 2.94E-04 3.51E-01 2.22E-07 5.30E-01 5.07E-01
3 131,562,955 rs59025993 INT CPNE4 6.70E-02 2.91E-03 8.01E-01 5.29E-01 2.90E-03 8.26E-01 2.18E-06 4.70E-01 8.47E-01
3 131,563,467 rs7632654 INT CPNE4 5.69E-02 9.41E-04 6.47E-01 5.90E-01 2.74E-03 8.32E-01 2.06E-06 2.69E-01 8.37E-01
3 131,563,872 rs6763315 INT CPNE4 5.74E-02 9.41E-04 6.43E-01 5.90E-01 2.79E-03 8.32E-01 2.06E-06 2.69E-01 8.42E-01
3 131,563,898 rs6787747 INT CPNE4 3.91E-02 1.32E-03 8.78E-01 6.98E-01 2.11E-03 8.85E-01 2.89E-06 4.32E-01 7.22E-01
3 131,565,157 rs67078110 INT CPNE4 5.70E-02 9.41E-04 6.46E-01 5.90E-01 2.75E-03 8.32E-01 2.06E-06 2.69E-01 8.38E-01
3 131,565,742 rs66506820 INT CPNE4 3.72E-02 8.80E-04 8.17E-01 7.83E-01 2.67E-03 8.24E-01 1.90E-06 4.82E-01 8.38E-01
3 131,568,832 rs4854626 INT CPNE4 4.81E-02 1.09E-03 7.48E-01 6.72E-01 2.78E-03 8.98E-01 1.75E-06 4.11E-01 8.60E-01
13 101,436,664 rs1158451 INT NALCN-AS1 3.67E-02 1.34E-06 1.07E-01 1.64E-01 1.19E-01 4.58E-02 4.82E-07 8.15E-01 7.24E-02
13 101,439,553 rs912368 INT NALCN-AS1 3.46E-02 1.00E-06 1.03E-01 1.52E-01 1.20E-01 4.01E-02 4.25E-07 8.10E-01 6.91E-02






Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
13 101,443,896 rs1983323 INT NALCN-AS1 5.37E-02 3.30E-06 9.66E-02 2.36E-01 1.27E-01 8.08E-02 4.60E-07 7.98E-01 6.54E-02
13 101,444,140 rs912371 INT NALCN-AS1 5.81E-02 4.28E-06 9.71E-02 2.57E-01 1.27E-01 9.33E-02 4.72E-07 7.98E-01 6.59E-02
13 101,447,275 rs7337962 INT NALCN-AS1 7.44E-02 2.43E-06 5.53E-02 3.28E-01 1.30E-01 6.37E-02 5.31E-07 4.77E-01 6.61E-02
13 101,447,967 rs4772330 INT NALCN-AS1 6.17E-02 2.27E-06 6.96E-02 2.58E-01 1.35E-01 6.10E-02 5.32E-07 6.20E-01 6.25E-02
13 101,448,466 rs6491581 INT NALCN-AS1 5.59E-02 8.12E-07 5.18E-02 2.14E-01 1.46E-01 4.45E-02 2.35E-07 6.27E-01 4.26E-02
13 101,448,738 rs6491582 INT NALCN-AS1 4.74E-02 1.88E-06 9.02E-02 2.37E-01 1.10E-01 5.71E-02 4.68E-07 6.54E-01 8.02E-02
13 101,451,472 rs4771372 INT NALCN-AS1 7.80E-02 1.06E-06 3.58E-02 2.78E-01 1.64E-01 3.81E-02 5.24E-07 4.17E-01 4.65E-02
13 101,453,076 rs1853555 INT . 1.45E-01 1.16E-05 3.96E-02 5.65E-01 1.52E-01 1.64E-01 4.63E-07 4.33E-01 5.01E-02
13 101,453,397 rs2093797 INT NALCN-AS1 6.96E-02 1.91E-06 5.48E-02 2.56E-01 1.56E-01 5.51E-02 5.27E-07 5.87E-01 5.02E-02
13 101,455,716 rs8001939 INT . 4.81E-02 1.07E-05 1.71E-01 3.64E-01 6.72E-02 1.14E-01 1.20E-06 6.24E-01 1.85E-01
13 101,456,163 rs7139965 INT . 4.00E-02 1.06E-05 2.06E-01 3.61E-01 5.39E-02 1.17E-01 1.11E-06 6.42E-01 2.24E-01
13 101,457,062 rs2147096 INT . 3.16E-02 1.81E-05 3.05E-01 2.54E-01 6.31E-02 1.34E-01 1.81E-06 9.79E-01 2.19E-01
13 101,457,472 rs4771374 INT . 3.01E-02 1.68E-05 3.10E-01 2.68E-01 5.59E-02 1.45E-01 1.27E-06 9.79E-01 2.24E-01
13 101,457,546 rs4771375 INT . 6.86E-02 1.30E-05 1.23E-01 3.19E-01 1.22E-01 1.71E-01 4.91E-07 9.25E-01 7.06E-02
13 101,458,912 rs9518178 INT NALCN-AS1 2.19E-02 4.17E-06 2.61E-01 2.43E-01 4.31E-02 6.04E-02 1.43E-06 6.57E-01 2.89E-01
13 101,459,414 rs4772334 INT . 1.99E-02 7.87E-06 3.41E-01 2.34E-01 4.03E-02 9.24E-02 1.31E-06 8.64E-01 2.99E-01
13 101,459,509 rs4771376 INT NALCN-AS1 2.45E-02 5.53E-06 2.60E-01 2.75E-01 4.22E-02 7.17E-02 1.45E-06 6.40E-01 2.95E-01
13 101,460,534 rs2181726 INT . 6.05E-02 1.03E-05 1.31E-01 3.76E-01 8.57E-02 1.45E-01 5.57E-07 7.07E-01 1.15E-01
13 101,461,657 rs4771378 INT . 1.17E-01 4.29E-04 2.66E-01 9.41E-01 3.20E-02 7.27E-01 8.85E-07 5.89E-01 3.28E-01
13 101,461,945 rs4771379 INT . 1.16E-01 4.22E-04 2.66E-01 9.43E-01 3.19E-02 7.22E-01 8.89E-07 5.86E-01 3.29E-01
13 101,462,514 rs6491585 INT . 2.64E-01 1.03E-03 1.32E-01 6.55E-01 6.15E-02 8.08E-01 2.96E-06 3.18E-01 2.54E-01
13 101,462,664 rs1924278 INT . 1.44E-01 3.51E-05 6.80E-02 8.43E-01 7.74E-02 2.69E-01 6.00E-07 3.03E-01 1.32E-01




V. Summary of Bivariate Analyses 
All top bivariate results within AAs and EAs from both domains and facets were collected and organized into Tables 16 – 17.  
 
Table 16. Top GWAS Results of Bivariate AA Analyses for NEO Domains and Neuroticism Facets Meta-analyzed with Results 
from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
Trait Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
Depression 3 54,343,019 rs6445646 INT CACNA2D3 9.36E-04 1.00E-02 3.34E-02 4.93E-06 6.83E-01 6.12E-05 5.22E-01 2.04E-02 3.25E-01
Depression 5 116,019,417 rs10072088 . Near SEMA6A 1.47E-02 1.17E-03 7.44E-01 3.19E-06 4.10E-01 3.50E-05 8.23E-01 2.13E-02 2.33E-01
Openness to Experience 7 17,133,514 rs7801891 . . 2.04E-02 1.51E-03 8.19E-01 4.91E-08 9.33E-02 1.05E-07 2.24E-01 3.37E-02 2.35E-01
Hostility 7 100,624,309 rs11772086 INT MUC12 9.39E-03 1.42E-02 2.03E-01 3.07E-07 3.10E-01 6.54E-05 4.19E-01 1.35E-03 5.06E-01
Agreeableness 7 150,652,419 rs876088 INT KCNH2 1.55E-03 9.84E-04 2.05E-01 9.69E-08 6.54E-01 2.15E-06 7.05E-01 8.43E-03 7.81E-01
Openness to Experience 8 18,199,560 rs34290224 . . 1.08E-01 2.01E-02 9.66E-01 7.65E-08 1.07E-02 7.29E-05 3.32E-01 2.74E-04 1.39E-02
Vulnerability to Stress 10 63,413,315 rs7907869 . . 4.34E-05 3.24E-03 4.42E-03 4.11E-08 5.21E-01 7.94E-05 9.89E-01 1.24E-04 4.18E-01
Vulnerability to Stress 10 63,416,969 rs1456280 . . 2.21E-04 5.46E-03 1.38E-02 1.20E-07 7.74E-01 9.58E-05 8.32E-01 3.31E-04 6.07E-01




Table 17. Top GWAS Results of Bivariate EA Analyses for NEO Domains and Neuroticism Facets Meta-analyzed with Results 
from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS
Trait Chr Pos SNP Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA
Neuroticism 2 54,275,162 rs13414393 INT LOC100506338 2.33E-05 9.62E-02 2.44E-05 9.59E-01 2.58E-08 3.05E-01 2.47E-04 1.85E-01 2.52E-05
Neuroticism 2 54,301,064 rs6545384 INT LOC100506338 1.35E-06 1.75E-03 2.26E-04 2.68E-01 5.20E-08 4.82E-01 8.70E-05 3.74E-01 1.10E-04
Neuroticism 2 54,312,153 rs1058320 . . 3.88E-05 3.05E-02 3.17E-04 9.86E-01 5.28E-08 5.90E-01 1.09E-04 4.95E-01 9.44E-05
Neuroticism 2 54,313,836 rs7591194 . . 2.07E-05 2.04E-02 2.61E-04 8.50E-01 4.20E-08 7.41E-01 1.09E-04 4.85E-01 7.66E-05
Neuroticism 2 54,314,610 rs7560947 . . 9.96E-06 1.99E-02 1.12E-04 6.34E-01 5.18E-08 7.56E-01 1.13E-04 2.60E-01 9.03E-05
Neuroticism 2 54,328,837 rs10207537 . . 4.79E-06 1.10E-02 1.06E-04 5.18E-01 3.73E-08 9.14E-01 7.71E-05 2.51E-01 8.89E-05
Neuroticism 2 54,343,108 rs9808326 INT ACYP2 1.80E-05 3.14E-02 1.19E-04 6.78E-01 1.00E-07 6.95E-01 2.27E-04 2.59E-01 9.78E-05
Vulnerability to Stress 7 75,607,155 rs76021834 INT POR 5.34E-06 4.69E-03 3.40E-04 6.59E-01 1.58E-08 5.10E-01 4.32E-04 9.16E-01 9.58E-06
Anxiety 7 75,611,149 rs10954732 INT POR 3.67E-07 3.57E-02 6.36E-07 3.57E-02 8.87E-07 2.89E-01 4.89E-02 4.38E-02 3.17E-06
Vulnerability to Stress 7 75,611,149 rs10954732 INT POR 8.72E-07 6.38E-02 6.36E-07 2.76E-01 2.49E-08 8.04E-01 2.11E-03 4.38E-02 3.17E-06
Vulnerability to Stress 7 75,611,355 rs2286821 INT POR 3.71E-06 1.22E-01 1.14E-06 5.06E-01 2.72E-08 5.53E-01 2.68E-03 7.76E-02 2.68E-06
Vulnerability to Stress 7 75,611,756 rs3815455 INT POR 3.30E-05 1.84E-02 5.13E-04 7.42E-01 1.78E-07 6.99E-01 1.83E-03 9.62E-01 2.81E-05
Vulnerability to Stress 7 75,612,803 rs41301394 INT POR 4.99E-04 1.56E-01 6.12E-04 5.34E-01 2.47E-07 4.12E-01 2.18E-03 9.86E-01 3.31E-05
Vulnerability to Stress 7 75,613,998 rs4732514 INT POR 4.67E-06 5.48E-02 8.30E-06 4.11E-01 8.46E-08 9.16E-01 2.58E-03 1.55E-01 9.23E-06
Extraversion 7 84,952,631 rs12534830 . near SEMA3D 1.49E-05 2.63E-01 1.19E-06 9.02E-01 1.73E-08 1.36E-01 7.56E-04 4.52E-02 6.20E-06
Impulsiveness 7 84,952,631 rs12534830 . near SEMA3D 6.45E-08 6.81E-03 1.19E-06 4.34E-03 2.80E-06 4.08E-02 7.64E-02 4.52E-02 6.20E-06
Extraversion 7 84,995,484 rs12536813 . near SEMA3D 4.29E-05 3.36E-01 2.93E-06 8.45E-01 2.18E-08 1.25E-01 1.46E-03 1.20E-01 4.07E-06
Impulsiveness 7 84,995,484 rs12536813 . near SEMA3D 2.12E-06 5.45E-02 2.93E-06 8.10E-02 1.86E-06 3.27E-01 7.30E-02 1.20E-01 4.07E-06
Anxiety 14 92,871,852 rs4904893 INT SLC24A4 5.73E-07 9.07E-05 1.41E-03 3.70E-02 1.48E-06 9.96E-02 5.27E-05 2.00E-01 2.75E-03
Vulnerability to Stress 15 40,153,847 rs275747 INT GPR176 9.83E-07 2.62E-02 4.09E-06 1.98E-02 8.08E-06 1.55E-01 8.04E-02 5.27E-02 2.04E-05
Impulsiveness 15 40,155,759 rs8027511 INT GPR176 1.07E-05 3.92E-01 2.03E-07 6.12E-01 6.78E-08 8.56E-01 1.35E-01 3.09E-01 2.00E-08
Impulsiveness 15 40,194,134 rs189936 INT GPR176 1.37E-04 1.43E-01 1.26E-04 8.51E-01 1.78E-07 6.12E-01 5.43E-03 7.49E-01 9.06E-06
Depression 15 62,584,178 rs1818320 . . 1.40E-04 2.02E-02 2.38E-03 9.45E-01 3.20E-07 6.06E-01 3.50E-03 4.63E-01 2.69E-05
Depression 15 62,587,650 rs11856956 . . 8.83E-05 1.82E-02 1.61E-03 8.80E-01 9.72E-08 7.51E-01 1.36E-03 5.34E-01 2.02E-05
Depression 15 62,596,220 rs10851713 . . 8.12E-05 5.29E-02 3.51E-04 9.93E-01 1.79E-07 8.31E-01 1.58E-03 7.85E-01 3.25E-05
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VI. NEO Facet and CaD Pathway Analysis  
The pathway analysis from IPA for the neuroticism facet / CaD results is shown 
in Figure 2.  
 
Figure 2. Pathway Analysis Results of Genes within NEO Facet and CaD Meta-analyses. 
 
The network represents the top network with the most molecules (21) and is called 
Cellular Compromise, Cell Morphology, Cellular Assembly and Organization. Similar to 
the domain pathway analysis, it contains many molecules that interact with Akt and the 
PI3K complex.  
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VII. Summary 
Within the NEO domain analyses (Tables 4-8), GWS results (p<5.00E-08) in the 
extraversion domain bivariate EA analysis between the NEO domain and CaD include 
rs12534830 (p=1.73E-08) and rs12536813 (p=2.18E-08), which are intergenic SNPs 
approximately 200 kb from the SEMA3D gene whose protein product induces the 
collapse and paralysis of neuronal growth cones. Other SNPs ~200 kb away from a gene 
have been known to have an effect such as a SNP in the vicinity of DGAT1 (Hayes et al., 
2009). The two GWS SNPs in our study were significant in the bivariate EA analysis 
with the significance primarily driven by CaD. Multiple GWS SNPs were found within 
the bivariate EA analysis of the neuroticism domain, which had three GWS SNPs 
(rs13414393, p=2.58E-08; rs10207537, p=3.73E-08; rs7591194, p=4.20E-08) in one 
region and three near-GWS SNPs in the same region (rs7560947, p=5.18E-08; 
rs6545384, p=5.20E-08; rs1058320, p=5.28E-08). They’re all located near 
LOC100506338, an uncharacterized locus on chromosome 2. These statistically 
significant results were primarily driven by the CaD analysis. Within the bivariate AA 
analysis of the domain openness to experience, rs7801891 was the only GWS SNP 
(p=4.91E-08) and its significance was primarily derived from the personality trait 
analysis. Other SNPs in the bivariate AA domains approached, but did not reach GWS 
(rs34290224 in openness to experience, p=7.65E-08; rs876088 in agreeableness, 
p=9.69E-08). Rs34290224 has approximately equal contributions from both traits while 
the results from rs876088 were primarily driven by the personality trait. 
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The most significant results of the neuroticism facet analyses were within the 
analysis considering the facet vulnerability to stress as a single outcome. First, in the 
NEO personality meta-analysis, there was a GWS SNP (rs12047995, p=3.55E-08) within 
the SLC35F3 gene. It is surrounded by five other top SNPs, two of which have p<1.00E-
07 (rs6702481, p=8.94E-08; rs11587514, p=8.65E-08). Evidence for significance was 
approximately the same from both AAs and EAs. SLC35F3 is a solute carrier, many of 
which have been repeatedly implicated in addiction. Also within the same vulnerability to 
stress facet, another major GWS result (rs7907869, p=4.11E-08) was found within the 
bivariate AA analysis. Its closest gene is C10orf107, an open reading frame that codes for 
an uncharacterized protein. The evidence was also from both AAs and EAs almost 
equally, with the AA analysis having slightly higher p-values. Two other near-GWS hits 
(rs7907869 p=4.11E-08; rs1456280 p=1.20E-07) are also in the same linkage 
disequilibrium (LD) block on chromosome 10. The facet vulnerability to stress also has 
three GWS SNPs (rs76021834, p=1.58E-08; rs2286821, p=2.72E-08; rs10954732, 
p=2.49E-08) and one near-GWS SNP (rs4732514, p=8.46E-08) in the POR gene of the 
bivariate EA analysis. Rs10954732 was also near-GWS in the anxiety bivariate EA 
analysis (p=8.87E-07). POR encodes a P450 cytochrome oxioreductase. The CaD GWAS 
primarily contributed to all of these results. A functionally relevant solute carrier 
sodium/potassium/calcium exchanger (SCL24A4) was reported within the anxiety 
bivariate EA analysis (rs4904893, p=1.48E-06) with results primarily driven by the 
anxiety facet data. No SNPs were found to be statistically significant or functionally 
relevant within both the neuroticism domain analysis and one of the facets. 
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In summary, a major gene set in all the results was the semaphorin group, which 
codes for proteins that induce the collapse and paralysis of neuronal growth cones. 
Within the bivariate EA analysis of impulsiveness, two near-GWS hits are approximately 
200 kb from SEMA3D (rs12536813, p=2.18E-08; rs12534830, p=2.80E-06). The same 
SNP rs12534830 was highly significant within the meta-analysis of all four groups of the 
impulsiveness analysis (both ethnicities and both traits, p=6.45E-08). These two SNPs 
were GWS in the bivariate EA analysis of extraversion domain (Table 17) with evidence 
driven primarily by CaD for both analyses. Two SNPs within the impulsiveness facet of 
the combined meta-analysis of all groups (rs1224671, p=2.50E-06; rs2164371, p=2.49E-
06) are located in introns of SEMA6D. Notable near-GWS results (p<1.00E-07) include 
rs1955383 (p=9.26E-08) within the impulsiveness meta-analysis and rs1167639 
(p=7.07E-08) within self-consciousness for NEO AA only. Rs1955383 significance was 
primarily driven by AAs. It is located within the PPFIA2 gene that encodes a protein 
tyrosine phosphatase while rs1167639 is near the RASSF8 tumor suppressor gene. 
Rs1955383 was surrounded by twelve other SNPs within the PPFIA2 gene that have 




Many of the most significant findings across all of the analyses have prior links to 
addiction biology. Prior association studies have linked variants near rs7801891 to 
caffeine dependence (Cornelis et al., 2011), which in this study was significantly 
associated with openness to experience for AAs. SNPs in two solute carrier genes, 
SLC24A4 and SLC35F3 approached or were GWS in the overall analysis of anxiety and 
in the NEO analysis of vulnerability to stress, respectively. These transport ions and other 
solutes across membranes and signaling have been linked to addiction in multiple prior 
studies (Gelernter et al., 2014, Biernacka et al., 2012).  
A major theme among the CaD analyses was a link to schizophrenia. In a 
systematic meta-analysis of 11 different studies from 1966 to 2005, researchers 
concluded cannabis use is a risk factor of developing schizophrenia or schizophrenia-like 
psychotic illnesses and increases the risk by approximately three-fold (Semple et al., 
2005). One study found association of schizophrenia with the PI4K2B gene (Houlihan et 
al., 2009). PI4K2B is in the same family as a major protein within the pathway analysis 
of the NEO domain results and it has also been associated with CaD in previous studies 
by our laboratory (Sherva et al., in preparation).  
Multiple studies have linked the SEMA3D gene to schizophrenia (Gregorio et al., 
2009; Fujii et al., 2011). Within our studies, several analyses across different domains 
and traits reported top hits within or nearby a semaphorin gene (rs12534830 and 
rs12536813 near SEMA3D in both extraversion and impulsiveness bivariate EA; 
rs10072088 near SEMA6A in depression bivariate AA; rs2164371 within SEMA6A in 
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impulsiveness NEO). In addition, semaphorin signaling in neurons (p=3.62E-03) was a 
major pathway within the analysis using the NEO domain results. The same pathway was 
reported in the conglomeration of all the facet results with p=7.96E-03. 
Despite these promising connections between cannabis and schizophrenia, not all 
studies have shown a strong correlation. A systematic search of all English language 
articles before April 2012 (31 articles total) revealed no consistent connections on the 
role of the endocannabinoid system in schizophrenia (Ferretjans et al., 2012). Therefore, 
additional studies are necessary in order to solidify the connection between these traits.  
In comparison to a mathematical bivariate analysis approach (Liu et al., 2009) or 
the bivariate extension of the two-level Haseman-Elston regression method (Jun et al., 
2012), the current study used meta-analysis as a means of estimating a joint effect of one 
SNP on two different traits. The bivariate approach was not employed here because 
personality trait information was available for one data set only. Application of these 
advanced mathematical models to analyze the effect of one SNP on two traits in a much 
larger sample would provide more accurate results. Our study has a modest sample size 
for complex traits and may have produced some false negative results.  
Another aspect of the results to point out was that all associated SNPs are either 
intergenic or intronic. SNPs outside of genes may not be as clearly defined or definitively 
linked to regulation of a gene and therefore, a biological function. Some GWS SNPs are 
approximately 200 kb from the closest genes and may not be linked to the function of 
those genes. All SNP genotype probabilities were imputed based on reference panels for 
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EAs and AAs. However, only SNPs with quality scores of > 80% were included in the 
association analysis.  
Other limitations involve the individuals themselves. Only 84% of people 
surveyed for personality provided valid results. The missing 16% may have contained 
crucial data that could have altered the significance of many analyses. A similar situation 
of unknown phenotypes is also present for all addiction diagnoses. Persons who have not 
been exposed to cannabis have an unknown phenotype for addiction. This is a major 
limitation for all human studies of addiction. In our study, this was controlled for by 
removing unexposed persons from the analysis. Additionally, the impact of this limitation 
was reduced with the use of the ordinal trait instead of the dichotomous, which is a major 
strength of our work. Finally, our work does not include any formal replication sets. 
Replication in independent samples is essential for validating association results by 
eliminating false positives.  
A future study will include three or more data sets, each with very large sample 
sizes to eliminate false positive and false negative results, respectively. One of the sample 
sets may include genotyped SNPs that can confirm the imputed data. The bivariate 
analysis will incorporate the Haseman-Elston regression method for increased accuracy. 
Further, this computational work can be translated into functional studies that may 
validate relevance and elucidate causative mechanisms. For example, brain gene 
expression profiles can be obtained of both CaD individuals and controls and compared 
for the significant variants found in this work.  
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Our study found multiple GWS hits within the regions of semaphorin genes, 
which have been previously associated with schizophrenia. To our knowledge, this is the 
first study to evaluate the association of genetic markers with a dual outcome of a 








Table A1. Top GWAS Results of NEO Domain Neuroticism Meta-Analyzed With Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
2 54,275,162 rs13414393 0.441 INT LOC100506338 2.33E-05 9.62E-02 2.44E-05 9.59E-01 2.58E-08 3.05E-01 2.47E-04 1.85E-01 2.52E-05 -0.292 1.360 0.109 0.213 0.418 0.446 0.415 0.466
2 54,301,064 rs6545384 0.409 INT LOC100506338 1.35E-06 1.75E-03 2.26E-04 2.68E-01 5.20E-08 4.82E-01 8.70E-05 3.74E-01 1.10E-04 -0.209 -1.490 -0.079 -0.194 0.322 0.485 0.329 0.465
2 54,312,153 rs1058320 0.436 . . 3.88E-05 3.05E-02 3.17E-04 9.86E-01 5.28E-08 5.90E-01 1.09E-04 4.95E-01 9.44E-05 0.158 -1.470 -0.057 -0.196 0.380 0.489 0.392 0.467
2 54,313,836 rs7591194 0.435 . . 2.07E-05 2.04E-02 2.61E-04 8.50E-01 4.20E-08 7.41E-01 1.09E-04 4.85E-01 7.66E-05 0.097 -1.470 -0.059 -0.198 0.377 0.490 0.389 0.468
2 54,314,610 rs7560947 0.425 . . 9.96E-06 1.99E-02 1.12E-04 6.34E-01 5.18E-08 7.56E-01 1.13E-04 2.60E-01 9.03E-05 0.092 -1.460 -0.095 -0.197 0.355 0.487 0.370 0.467
2 54,328,837 rs10207537 0.437 . . 4.79E-06 1.10E-02 1.06E-04 5.18E-01 3.73E-08 9.14E-01 7.71E-05 2.51E-01 8.89E-05 0.031 -1.500 -0.096 -0.196 0.378 0.490 0.384 0.475
2 54,343,108 rs9808326 0.429 INT ACYP2 1.80E-05 3.14E-02 1.19E-04 6.78E-01 1.00E-07 6.95E-01 2.27E-04 2.59E-01 9.78E-05 0.113 -1.390 -0.095 -0.195 0.368 0.483 0.377 0.468
3 131,555,963 rs1606513 0.235 INT CPNE4 3.21E-03 2.44E-05 9.05E-01 8.11E-01 2.15E-04 3.38E-01 1.28E-07 4.32E-01 4.92E-01 -0.344 -2.320 0.078 -0.040 0.228 0.245 0.251 0.228
3 131,556,537 rs12639530 0.238 INT CPNE4 2.20E-03 1.76E-05 8.35E-01 6.81E-01 2.13E-04 2.88E-01 1.33E-07 5.20E-01 4.86E-01 -0.376 -2.320 0.063 -0.041 0.234 0.245 0.257 0.229
3 131,560,408 rs2077634 0.238 INT CPNE4 2.35E-03 1.84E-05 8.50E-01 6.80E-01 2.37E-04 2.93E-01 1.35E-07 5.30E-01 5.07E-01 -0.372 -2.310 0.062 -0.039 0.235 0.245 0.256 0.229
4 157,527,974 rs4691363 0.102 . . 6.62E-07 2.18E-07 4.71E-02 5.36E-05 2.10E-03 4.57E-06 8.22E-03 4.30E-01 6.18E-02 1.810 1.750 0.096 0.194 0.132 0.083 0.138 0.074
4 157,528,080 rs1402780 0.102 . . 6.68E-07 2.22E-07 4.70E-02 5.45E-05 2.10E-03 4.68E-06 8.20E-03 4.30E-01 6.17E-02 1.800 1.750 0.096 0.194 0.133 0.083 0.138 0.074
4 157,528,247 rs939688 0.102 . . 7.07E-07 2.17E-07 4.91E-02 5.46E-05 2.20E-03 4.57E-06 8.20E-03 4.34E-01 6.42E-02 1.810 1.750 0.094 0.192 0.132 0.083 0.138 0.074
4 157,528,765 rs4690868 0.104 . . 2.48E-07 1.19E-07 3.26E-02 1.55E-05 2.09E-03 2.23E-06 8.16E-03 2.92E-01 6.16E-02 1.840 1.740 0.128 0.194 0.137 0.083 0.142 0.074
4 157,528,928 rs4690869 0.102 . . 4.47E-07 2.22E-07 3.65E-02 3.30E-05 2.09E-03 4.68E-06 8.20E-03 3.31E-01 6.15E-02 1.800 1.750 0.119 0.194 0.133 0.083 0.135 0.074
4 157,529,699 rs13129297 0.101 . . 4.31E-07 2.11E-07 3.64E-02 3.09E-05 2.11E-03 4.30E-06 8.34E-03 3.30E-01 6.15E-02 1.820 1.750 0.120 0.194 0.132 0.083 0.135 0.074
4 157,529,838 rs13129704 0.101 . . 4.29E-07 2.10E-07 3.64E-02 3.06E-05 2.12E-03 4.25E-06 8.37E-03 3.30E-01 6.15E-02 1.820 1.750 0.120 0.194 0.132 0.083 0.135 0.074
4 157,530,001 rs10027485 0.101 . . 4.27E-07 2.09E-07 3.64E-02 3.05E-05 2.12E-03 4.22E-06 8.39E-03 3.30E-01 6.14E-02 1.820 1.750 0.120 0.194 0.132 0.083 0.135 0.074
4 157,530,046 rs12711310 0.101 . . 4.27E-07 2.09E-07 3.64E-02 3.04E-05 2.12E-03 4.20E-06 8.40E-03 3.30E-01 6.14E-02 1.820 1.750 0.120 0.194 0.132 0.083 0.135 0.074
4 157,530,060 rs12711311 0.101 . . 4.27E-07 2.09E-07 3.64E-02 3.04E-05 2.12E-03 4.20E-06 8.40E-03 3.30E-01 6.14E-02 1.820 1.750 0.120 0.194 0.132 0.083 0.135 0.074
4 157,530,695 rs4691364 0.099 . . 1.58E-07 7.62E-08 2.95E-02 1.93E-05 1.23E-03 3.94E-06 3.75E-03 2.63E-01 6.12E-02 1.840 1.960 0.139 0.203 0.131 0.077 0.134 0.071




Table A2. Top GWAS Results of NEO Domain Extraversion Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
1 23,785,760 rs7551124 0.239 INT ASAP3 1.91E-05 4.38E-02 7.63E-05 4.50E-01 5.38E-07 9.37E-01 1.76E-03 1.99E-01 8.85E-05 0.023 -1.690 -0.105 -0.269 0.378 0.139 0.380 0.130
1 23,788,994 rs10917383 0.239 INT ASAP3 1.87E-05 4.34E-02 7.53E-05 4.49E-01 5.23E-07 9.40E-01 1.75E-03 2.00E-01 8.64E-05 0.022 -1.690 -0.105 -0.269 0.377 0.139 0.380 0.130
2 127,546,999 rs6716185 0.098 . . 4.95E-07 1.04E-04 1.10E-03 3.01E-05 2.42E-03 7.32E-05 1.69E-01 8.02E-02 5.84E-03 -2.260 -0.796 -0.245 -0.206 0.069 0.123 0.072 0.116
2 127,547,766 rs62159603 0.098 . . 4.51E-07 9.52E-05 1.09E-03 2.70E-05 2.40E-03 6.53E-05 1.68E-01 7.94E-02 5.83E-03 -2.280 -0.798 -0.245 -0.206 0.069 0.123 0.072 0.116
2 127,549,510 rs62159604 0.098 . . 3.89E-07 8.27E-05 1.06E-03 2.34E-05 2.33E-03 5.66E-05 1.64E-01 7.76E-02 5.80E-03 -2.290 -0.804 -0.246 -0.206 0.069 0.123 0.072 0.116
2 207,954,584 rs114657667 0.076 INT KLF7 4.51E-01 1.91E-01 2.57E-02 3.45E-03 1.22E-01 4.30E-01 2.79E-01 2.75E-08 2.61E-01 0.404 0.791 -0.620 0.121 0.084 0.064 0.087 0.071
5 1,228,323 rs58933348 0.313 INT SLC6A18 3.13E-05 1.19E-05 1.04E-01 3.83E-04 1.52E-02 1.58E-05 8.32E-02 7.30E-01 8.22E-02 1.240 0.755 0.030 0.108 0.364 0.278 0.356 0.275
5 2,655,779 rs16870234 0.365 . . 4.71E-03 2.87E-01 4.20E-03 8.75E-04 3.96E-01 5.06E-01 3.93E-01 9.60E-06 6.72E-01 0.193 0.344 0.353 0.026 0.534 0.251 0.513 0.239
5 7,519,762 rs6867567 0.297 INT ADCY2 4.27E-01 2.23E-02 3.05E-01 3.85E-01 7.01E-02 3.46E-01 6.52E-06 8.24E-01 2.75E-01 -0.259 1.920 -0.019 -0.071 0.445 0.218 0.428 0.173
5 113,327,356 rs296496 0.200 . . 1.70E-01 8.95E-01 4.71E-02 1.65E-02 7.87E-01 5.64E-01 6.51E-01 7.79E-06 5.01E-01 0.294 -0.187 -0.576 0.037 0.086 0.276 0.089 0.290
5 118,349,058 rs17144869 0.123 . . 2.26E-04 1.65E-01 1.88E-04 7.45E-01 4.05E-06 7.67E-01 1.52E-02 3.84E-01 8.23E-05 0.179 -1.190 -0.146 -0.234 0.055 0.164 0.055 0.181
5 118,495,671 rs11742202 0.150 INT DMXL1 1.20E-03 5.05E-01 1.51E-04 7.02E-01 3.65E-06 2.55E-01 2.21E-02 4.36E-01 4.75E-05 0.625 -1.030 -0.133 -0.227 0.066 0.200 0.067 0.221
5 147,038,335 rs13162410 0.288 INT LOC153469 3.84E-05 5.80E-01 3.64E-07 1.82E-02 6.66E-04 6.02E-01 8.05E-01 2.07E-03 5.01E-05 -0.143 -0.116 -0.253 -0.262 0.456 0.173 0.450 0.156
5 147,038,335 rs13162410 0.288 INT LOC153469 3.84E-05 5.80E-01 3.64E-07 1.82E-02 6.66E-04 6.02E-01 8.05E-01 2.07E-03 5.01E-05 -0.143 -0.116 -0.253 -0.262 0.456 0.173 0.450 0.156
5 147,054,820 rs12653567 0.182 . . 2.73E-03 6.73E-01 8.06E-06 4.35E-01 9.88E-04 4.73E-01 8.63E-01 3.58E-02 7.05E-05 0.230 -0.085 -0.208 -0.261 0.224 0.152 0.224 0.149
7 84,952,631 rs12534830 0.244 . near SEMA3D 1.49E-05 2.63E-01 1.19E-06 9.02E-01 1.73E-08 1.36E-01 7.56E-04 4.52E-02 6.20E-06 0.725 -1.480 -0.257 -0.260 0.113 0.343 0.117 0.342
7 84,995,484 rs12536813 0.226 . near SEMA3D 4.29E-05 3.36E-01 2.93E-06 8.45E-01 2.18E-08 1.25E-01 1.46E-03 1.20E-01 4.07E-06 0.921 -1.410 -0.233 -0.266 0.083 0.335 0.086 0.333
8 27,325,473 rs747111 0.222 INT CHRNA2 3.54E-04 3.07E-04 1.26E-01 2.58E-07 8.04E-01 7.61E-03 1.51E-02 1.16E-06 1.35E-01 -1.480 -1.000 -0.623 0.080 0.074 0.322 0.079 0.338
9 111,941,854 rs885505 0.358 INT EPB41L4B 7.69E-04 4.44E-05 4.17E-01 4.27E-05 3.70E-01 6.11E-06 2.92E-01 3.44E-01 7.39E-01 -1.250 -0.392 -0.081 -0.017 0.345 0.372 0.336 0.370
9 111,942,454 rs10759333 0.480 INT EPB41L4B 1.73E-03 1.51E-05 7.85E-01 2.27E-05 6.43E-01 5.69E-06 1.60E-01 2.48E-01 6.41E-01 -1.220 -0.519 -0.096 0.023 0.543 0.439 0.548 0.426
9 111,943,009 rs10816778 0.480 INT EPB41L4B 1.87E-03 1.53E-05 8.07E-01 2.31E-05 6.63E-01 5.50E-06 1.64E-01 2.54E-01 6.24E-01 -1.220 -0.513 -0.095 0.025 0.543 0.439 0.548 0.425
9 111,943,210 rs10114938 0.327 INT EPB41L4B 2.59E-02 1.01E-03 1.00E+00 9.34E-05 6.52E-01 9.10E-06 9.59E-01 4.48E-01 6.01E-01 1.230 -0.020 0.064 -0.030 0.367 0.304 0.364 0.295
9 111,943,276 rs7031103 0.480 INT EPB41L4B 2.05E-03 1.48E-05 8.41E-01 2.85E-05 6.59E-01 5.33E-06 1.63E-01 2.90E-01 6.27E-01 -1.220 -0.515 -0.088 0.025 0.544 0.438 0.548 0.425
10 125,509,947 rs2362675 0.311 INT CPXM2 3.47E-04 1.29E-01 5.27E-04 8.06E-01 7.10E-07 8.37E-01 4.00E-02 5.25E-01 3.30E-06 -0.058 -0.872 0.054 -0.273 0.446 0.232 0.436 0.200
10 125,510,357 rs10736932 0.310 INT CPXM2 2.49E-04 1.16E-01 4.10E-04 8.36E-01 4.67E-07 8.43E-01 3.19E-02 5.72E-01 2.82E-06 -0.055 -0.906 0.048 -0.275 0.445 0.231 0.434 0.200
10 125,524,323 rs1219743 0.148 INT CPXM2 1.16E-03 7.70E-01 3.37E-05 4.81E-01 8.52E-07 3.40E-01 1.29E-01 9.60E-01 5.60E-07 0.407 -0.722 -0.007 -0.324 0.111 0.176 0.112 0.176
14 32,336,134 rs1959074 0.156 . . 3.19E-03 3.44E-01 1.70E-03 1.30E-05 9.11E-01 2.74E-01 8.48E-01 3.21E-08 9.97E-01 -0.627 -0.085 -0.667 0.000 0.080 0.216 0.078 0.214




Table A3. Top GWAS Results of NEO Domain Openness to Experience Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
1 203,378,005 rs10920639 0.291 . . 8.93E-03 7.88E-04 6.43E-01 5.51E-01 3.19E-03 3.21E-01 8.11E-05 7.89E-01 4.55E-01 0.258 1.760 -0.022 0.048 0.429 0.199 0.398 0.193
1 203,380,765 rs10753942 0.242 . . 2.25E-03 2.02E-05 8.21E-01 1.14E-01 7.49E-03 3.94E-02 4.08E-05 9.89E-01 7.76E-01 0.566 1.850 -0.001 0.018 0.321 0.192 0.298 0.188
1 203,383,069 rs137956967 0.281 . . 3.08E-03 3.47E-05 8.34E-01 1.78E-01 5.93E-03 3.95E-02 8.89E-05 7.04E-01 6.05E-01 0.553 1.670 -0.032 0.032 0.363 0.232 0.330 0.228
1 203,383,898 rs10920644 0.429 . . 9.70E-03 2.17E-03 4.89E-01 3.54E-01 8.72E-03 5.72E-01 6.75E-05 4.40E-01 7.58E-01 0.150 1.650 0.066 0.018 0.627 0.296 0.587 0.287
1 203,384,102 rs2365601 0.285 . . 2.42E-03 2.10E-05 8.38E-01 1.52E-01 5.54E-03 2.59E-02 9.64E-05 6.53E-01 5.76E-01 0.595 1.640 -0.038 0.034 0.366 0.236 0.334 0.233
1 203,386,034 rs141929587 0.277 . . 9.05E-04 1.28E-05 6.23E-01 1.35E-01 1.94E-03 3.20E-02 3.18E-05 8.02E-01 4.41E-01 0.587 1.770 -0.022 0.048 0.351 0.234 0.318 0.230
1 203,387,513 rs16851575 0.260 . . 2.98E-03 2.33E-05 8.88E-01 1.30E-01 8.77E-03 3.54E-02 6.21E-05 8.62E-01 7.71E-01 0.554 1.790 -0.015 0.019 0.361 0.196 0.333 0.189
1 203,390,302 rs4638182 0.265 . . 3.16E-04 1.43E-07 9.60E-01 2.11E-02 5.64E-03 7.59E-04 3.58E-05 6.46E-01 7.05E-01 0.877 1.870 -0.038 0.025 0.374 0.196 0.348 0.188
1 203,390,784 rs4971224 0.264 . . 4.59E-04 2.23E-07 9.95E-01 2.95E-02 5.95E-03 1.04E-03 4.00E-05 5.78E-01 7.07E-01 0.856 1.890 -0.045 0.024 0.373 0.192 0.348 0.188
2 133,372,800 rs67992216 0.165 INT GPR39 5.95E-02 5.12E-01 5.01E-02 5.73E-07 6.33E-02 7.49E-03 4.24E-02 3.89E-06 4.20E-01 -1.330 0.905 -0.604 0.051 0.074 0.225 0.086 0.233
2 206,082,907 rs7564553 0.492 INT PARD3B 8.47E-05 1.35E-02 2.15E-03 8.51E-01 4.41E-07 4.19E-01 4.91E-03 4.93E-01 2.65E-05 0.217 0.927 -0.053 0.218 0.506 0.478 0.497 0.488
2 206,087,701 rs6435277 0.468 INT PARD3B 1.84E-04 3.65E-02 1.59E-03 9.38E-01 9.95E-07 4.72E-01 1.92E-02 4.53E-01 1.33E-05 0.188 0.779 -0.058 0.230 0.511 0.437 0.500 0.439
2 207,954,584 rs114657667 0.076 INT KLF7 1.30E-01 8.51E-01 2.57E-02 5.84E-03 6.93E-01 3.14E-01 3.94E-01 2.75E-08 2.61E-01 0.476 -0.570 -0.620 0.121 0.084 0.064 0.087 0.071
3 22,017,246 rs13097046 0.378 INT LOC100505836 3.02E-03 6.47E-05 7.25E-01 2.21E-01 4.15E-03 7.56E-02 5.87E-05 8.17E-01 5.57E-01 -0.517 -1.440 0.022 -0.030 0.269 0.452 0.257 0.470
3 22,017,747 rs56152519 0.150 INT LOC100505836 8.60E-03 2.25E-06 4.33E-01 2.34E-02 1.31E-01 7.94E-03 3.55E-05 7.31E-01 2.34E-01 -1.020 -1.840 -0.041 0.082 0.134 0.177 0.128 0.157
3 22,018,756 rs62248370 0.138 INT LOC100505836 1.18E-02 1.33E-05 5.55E-01 3.33E-02 1.38E-01 2.92E-02 4.03E-05 4.84E-01 2.30E-01 -0.934 -1.850 -0.092 0.082 0.107 0.175 0.100 0.157
3 22,019,084 rs34565874 0.136 INT LOC100505836 3.43E-02 4.88E-05 3.88E-01 1.23E-01 1.44E-01 8.18E-02 3.19E-05 7.52E-01 2.05E-01 -0.762 -1.890 -0.044 0.087 0.101 0.175 0.094 0.158
3 22,019,365 rs56006694 0.132 INT LOC100505836 2.94E-02 6.51E-05 4.73E-01 9.85E-02 1.47E-01 9.44E-02 3.57E-05 5.70E-01 2.06E-01 -0.734 -1.880 -0.078 0.087 0.095 0.174 0.087 0.157
3 22,019,860 rs17644807 0.132 INT LOC100505836 3.01E-02 6.60E-05 4.67E-01 9.89E-02 1.50E-01 9.44E-02 3.65E-05 5.72E-01 2.03E-01 -0.734 -1.870 -0.078 0.087 0.095 0.174 0.087 0.157
4 110,160,079 rs6533422 0.351 INT COL25A1 4.97E-03 5.32E-04 5.30E-01 7.22E-01 6.35E-04 2.56E-01 8.11E-05 4.13E-01 1.84E-01 -0.509 -1.430 0.109 -0.069 0.127 0.499 0.130 0.531
4 110,167,627 rs978633 0.467 INT COL25A1 2.27E-02 5.31E-06 2.74E-01 5.08E-01 1.44E-02 1.24E-02 5.30E-05 4.61E-02 9.63E-01 0.740 1.390 -0.180 0.003 0.641 0.366 0.629 0.324
5 147,038,335 rs13162410 0.288 INT LOC153469 1.10E-04 8.52E-01 3.64E-07 2.20E-03 1.38E-02 1.53E-01 1.83E-01 2.07E-03 5.01E-05 -0.378 0.656 -0.253 -0.262 0.456 0.173 0.450 0.156
7 17,133,514 rs7801891 0.085 . near caffeine dependence gene2.04E-02 1.51E-03 8.19E-01 4.91E-08 9.33E-02 1.05E-07 2.24E-01 3.37E-02 2.35E-01 -2.020 0.798 -0.243 0.144 0.118 0.059 0.129 0.055
7 84,952,631 rs12534830 0.244 . . 7.44E-06 1.80E-01 1.19E-06 2.51E-01 7.70E-07 8.71E-01 2.75E-02 4.52E-02 6.20E-06 0.072 -0.894 -0.257 -0.260 0.113 0.343 0.117 0.342
8 18,199,560 rs34290224 0.065 . . 1.08E-01 2.01E-02 9.66E-01 7.65E-08 1.07E-02 7.29E-05 3.32E-01 2.74E-04 1.39E-02 -1.720 0.776 -0.535 0.283 0.078 0.054 0.069 0.059
11 95,213,173 rs2000798 0.242 . . 1.25E-03 2.62E-01 7.92E-04 3.06E-06 8.30E-01 1.40E-01 9.79E-01 2.89E-08 8.04E-01 -0.753 -0.010 -0.670 -0.013 0.083 0.338 0.080 0.377
11 95,215,799 rs6483425 0.222 . . 1.26E-04 1.49E-01 1.02E-04 3.19E-07 5.27E-01 4.14E-02 8.99E-01 2.65E-08 3.78E-01 -0.956 0.049 -0.667 -0.047 0.105 0.302 0.100 0.319
14 32,336,134 rs1959074 0.156 . . 7.88E-02 4.17E-01 1.70E-03 1.76E-02 7.93E-01 1.39E-01 6.56E-01 3.21E-08 9.97E-01 0.776 -0.188 -0.667 0.000 0.080 0.216 0.078 0.214
15 40,155,759 rs8027511 0.089 INT GPR176 3.65E-05 6.51E-01 2.03E-07 2.27E-01 9.68E-06 4.68E-01 8.91E-01 3.09E-01 2.00E-08 -0.273 0.096 -0.115 -0.471 0.135 0.062 0.121 0.056




Table A4. Top GWAS Results of NEO Domain Agreeableness Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
2 207,954,584 rs114657667 0.076 INT KLF7 5.71E-02 7.00E-01 2.57E-02 2.42E-04 5.00E-01 8.59E-01 7.03E-01 2.75E-08 2.61E-01 -0.110 -0.321 -0.620 0.121 0.084 0.064 0.087 0.071
5 147,038,335 rs13162410 0.288 INT LOC153469 2.42E-05 4.78E-01 3.64E-07 1.67E-03 4.22E-03 1.25E-01 5.08E-01 2.07E-03 5.01E-05 -0.516 0.365 -0.253 -0.262 0.456 0.173 0.450 0.156
5 175,256,368 rs17767831 0.065 INT CPLX2 2.03E-04 9.37E-05 1.46E-01 2.29E-02 3.23E-03 1.73E-01 1.35E-05 5.44E-02 6.62E-01 -1.100 -3.550 -0.279 -0.042 0.060 0.060 0.080 0.063
5 175,268,350 rs6887312 0.152 INT CPLX2 4.71E-04 9.09E-06 5.05E-01 3.93E-02 4.49E-03 7.59E-02 2.76E-06 2.77E-01 9.53E-01 -0.753 -3.340 -0.105 -0.006 0.258 0.077 0.252 0.070
7 75,611,149 rs10954732 0.435 INT POR 5.55E-06 1.94E-01 6.36E-07 3.78E-02 2.49E-05 3.03E-01 4.26E-01 4.38E-02 3.17E-06 -0.348 -0.326 -0.160 -0.242 0.576 0.340 0.571 0.324
7 150,652,419 rs876088 0.146 INT KCNH2 1.55E-03 9.84E-04 2.05E-01 9.69E-08 6.54E-01 2.15E-06 7.05E-01 8.43E-03 7.81E-01 -2.160 0.222 -0.278 0.022 0.180 0.124 0.183 0.116
10 16,588,144 rs8181375 0.431 . . 1.00E-04 7.46E-07 4.65E-01 1.10E-03 2.05E-02 1.18E-05 1.18E-02 8.53E-01 3.10E-01 1.590 0.936 -0.016 0.054 0.416 0.452 0.414 0.437
10 49,774,924 rs75482917 0.393 INT ARHGAP22 3.70E-04 9.08E-03 1.48E-02 3.71E-07 7.69E-01 6.94E-05 5.79E-01 1.55E-03 4.37E-01 -1.320 0.225 -0.261 -0.040 0.488 0.315 0.488 0.325
11 11,410,281 rs10765845 0.414 INT GALNTL4 1.13E-02 7.32E-01 1.71E-04 3.43E-01 1.13E-02 6.19E-01 2.81E-01 3.75E-01 7.65E-05 0.174 -0.426 0.077 0.196 0.350 0.460 0.356 0.460
11 11,410,851 rs7945241 0.426 INT GALNTL4 5.82E-03 6.99E-01 4.03E-05 2.87E-01 6.34E-03 5.78E-01 2.26E-01 3.17E-01 1.72E-05 0.196 -0.478 0.086 0.212 0.360 0.472 0.372 0.472
11 11,412,180 rs4910331 0.420 INT GALNTL4 1.13E-02 7.51E-01 1.86E-04 2.61E-01 1.72E-02 3.55E-01 1.28E-01 5.20E-01 4.17E-05 0.331 -0.609 0.054 0.201 0.345 0.472 0.358 0.474
11 11,627,222 rs7932013 0.109 INT GALNTL4 2.76E-03 4.49E-06 8.76E-01 3.71E-02 3.12E-02 6.53E-05 1.59E-02 1.17E-01 3.72E-01 2.190 1.550 -0.180 0.099 0.139 0.103 0.151 0.070
12 82,141,237 rs2464735 0.242 INT PPFIA2 4.04E-03 9.03E-01 5.79E-05 1.68E-01 5.27E-07 1.31E-02 8.89E-03 4.00E-01 1.67E-05 0.895 -1.770 -0.068 -0.336 0.425 0.115 0.423 0.097
14 32,336,134 rs1959074 0.156 . . 1.42E-01 2.15E-01 1.70E-03 3.30E-03 5.40E-01 4.54E-01 3.06E-01 3.21E-08 9.97E-01 0.452 0.523 -0.667 0.000 0.080 0.216 0.078 0.214




Table A5. Top GWAS Results Of NEO Domain Conscientiousness Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
2 133,372,800 rs67992216 0.165 INT GPR39 3.38E-02 3.15E-01 5.01E-02 1.45E-07 7.71E-02 2.62E-03 6.02E-02 3.89E-06 4.20E-01 -2.040 0.968 -0.604 0.051 0.074 0.225 0.086 0.233
2 207,954,584 rs114657667 0.076 INT KLF7 2.12E-01 5.61E-01 2.57E-02 2.83E-03 3.43E-01 4.78E-01 9.40E-01 2.75E-08 2.61E-01 0.465 0.068 -0.620 0.121 0.084 0.064 0.087 0.071
3 24,793,811 rs4241533 0.143 . . 1.21E-03 4.21E-07 7.94E-01 2.68E-02 1.82E-02 3.32E-05 3.23E-03 1.20E-01 4.50E-01 2.820 1.650 -0.235 0.048 0.072 0.198 0.074 0.195
3 24,794,334 rs9856030 0.143 . . 1.11E-03 4.61E-07 8.32E-01 2.50E-02 1.78E-02 3.72E-05 3.20E-03 1.39E-01 4.45E-01 2.810 1.660 -0.223 0.049 0.072 0.198 0.074 0.195
3 24,795,211 rs6791127 0.142 . . 1.10E-03 4.51E-07 8.32E-01 2.52E-02 1.75E-02 3.65E-05 3.18E-03 1.36E-01 4.41E-01 2.820 1.660 -0.224 0.049 0.071 0.198 0.071 0.195
3 24,795,619 rs6776123 0.142 . . 1.19E-03 5.23E-07 8.30E-01 2.73E-02 1.75E-02 4.29E-05 3.19E-03 1.35E-01 4.41E-01 2.800 1.660 -0.224 0.049 0.071 0.198 0.071 0.195
3 24,797,525 rs7642276 0.143 . . 9.41E-04 3.22E-07 8.33E-01 2.11E-02 1.74E-02 2.45E-05 3.24E-03 1.35E-01 4.38E-01 2.860 1.650 -0.224 0.050 0.073 0.198 0.071 0.195
3 24,799,312 rs9882619 0.142 . . 5.77E-04 1.24E-07 8.48E-01 1.65E-02 1.32E-02 1.36E-05 2.18E-03 1.31E-01 4.18E-01 2.960 1.730 -0.227 0.052 0.073 0.196 0.071 0.195
3 24,802,235 rs6550899 0.142 . . 5.83E-04 1.53E-07 8.73E-01 1.82E-02 1.23E-02 1.58E-05 2.34E-03 1.27E-01 3.90E-01 2.940 1.720 -0.229 0.055 0.074 0.196 0.071 0.195
3 24,821,446 rs7621115 0.143 . . 9.69E-04 3.49E-07 8.36E-01 2.64E-02 1.46E-02 2.36E-05 3.60E-03 1.01E-01 3.79E-01 2.910 1.640 -0.246 0.057 0.074 0.196 0.071 0.195
3 24,833,960 rs5002695 0.144 . . 5.03E-04 2.21E-07 9.66E-01 1.26E-02 1.46E-02 1.26E-05 3.93E-03 1.68E-01 3.68E-01 3.100 1.660 -0.214 0.058 0.075 0.199 0.073 0.195
3 24,833,960 rs5002695 0.144 . . 5.03E-04 2.21E-07 9.66E-01 1.26E-02 1.46E-02 1.26E-05 3.93E-03 1.68E-01 3.68E-01 3.100 1.660 -0.214 0.058 0.075 0.199 0.073 0.195
3 24,834,316 rs6763459 0.148 . . 5.30E-05 7.17E-08 5.94E-01 1.39E-03 1.00E-02 5.44E-06 2.78E-03 6.24E-01 3.24E-01 3.140 1.750 -0.074 0.065 0.083 0.199 0.086 0.196
3 24,834,316 rs6763459 0.148 . . 5.30E-05 7.17E-08 5.94E-01 1.39E-03 1.00E-02 5.44E-06 2.78E-03 6.24E-01 3.24E-01 3.140 1.750 -0.074 0.065 0.083 0.199 0.086 0.196
3 24,834,378 rs4361227 0.193 . . 1.39E-04 2.12E-05 2.06E-01 1.16E-03 2.61E-02 4.59E-05 7.01E-02 8.72E-01 1.54E-01 2.550 0.948 0.023 0.087 0.104 0.259 0.105 0.262
5 147,038,335 rs13162410 0.288 INT LOC153469 5.21E-05 6.53E-01 3.64E-07 1.29E-02 1.38E-03 4.93E-01 9.24E-01 2.07E-03 5.01E-05 -0.242 0.054 -0.253 -0.262 0.456 0.173 0.450 0.156
7 75,611,149 rs10954732 0.435 INT POR 5.77E-04 7.45E-01 6.36E-07 1.52E-01 9.06E-04 8.46E-01 4.78E-01 4.38E-02 3.17E-06 -0.066 0.313 -0.160 -0.242 0.576 0.340 0.571 0.324
8 20,095,572 rs11204103 0.439 . . 2.32E-03 1.33E-01 5.83E-03 2.49E-01 4.52E-07 5.62E-01 3.50E-03 2.67E-01 3.85E-05 0.220 -1.310 0.095 -0.218 0.425 0.459 0.420 0.446
10 49,775,175 rs935295 0.402 INT ARHGAP22 5.53E-03 2.05E-01 9.17E-03 5.17E-07 4.87E-01 7.67E-05 1.07E-02 1.97E-03 3.03E-01 -1.360 1.130 -0.250 -0.054 0.508 0.315 0.512 0.323
10 125,524,323 rs1219743 0.148 INT CPXM2 4.68E-05 1.32E-01 3.37E-05 9.21E-01 1.07E-07 9.31E-01 2.97E-02 9.60E-01 5.60E-07 -0.049 -1.200 -0.007 -0.324 0.111 0.176 0.112 0.176
12 13,911,777 rs10492136 0.119 INT GRIN2B 4.03E-04 3.39E-05 3.22E-01 4.12E-05 2.63E-01 3.58E-06 3.07E-01 4.10E-01 5.25E-01 -2.400 -0.761 -0.089 -0.053 0.144 0.087 0.156 0.102
12 13,911,933 rs73300369 0.117 INT GRIN2B 1.08E-03 1.23E-04 3.65E-01 1.86E-04 2.81E-01 1.81E-05 3.41E-01 5.00E-01 5.25E-01 -2.310 -0.711 -0.075 -0.053 0.139 0.086 0.151 0.102
12 13,914,816 rs7316902 0.466 INT GRIN2B 1.23E-04 1.26E-06 4.49E-01 1.30E-05 1.96E-01 1.77E-06 5.55E-02 2.90E-01 8.50E-01 -1.670 -0.791 -0.089 -0.010 0.359 0.526 0.373 0.551
12 13,919,214 rs2284416 0.474 INT GRIN2B 3.22E-04 9.34E-06 4.19E-01 5.32E-05 2.11E-01 1.66E-05 6.83E-02 2.59E-01 8.39E-01 -1.490 -0.762 -0.095 -0.011 0.375 0.528 0.397 0.550
14 32,336,134 rs1959074 0.156 . . 9.06E-03 6.56E-01 1.70E-03 1.79E-04 8.44E-01 7.65E-01 7.38E-01 3.21E-08 9.97E-01 -0.196 -0.180 -0.667 0.000 0.080 0.216 0.078 0.214
15 40,155,759 rs8027511 0.089 INT GPR176 3.08E-04 7.53E-01 2.03E-07 6.65E-01 1.03E-05 7.81E-01 8.72E-01 3.09E-01 2.00E-08 0.138 0.126 -0.115 -0.471 0.135 0.062 0.121 0.056




Table A6. Top GWAS Results of Neuroticism Facet Anxiety Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
3 131,536,917 rs16837870 0.192 INT CPNE4 9.02E-02 3.07E-03 6.72E-01 3.26E-01 1.91E-03 7.85E-01 1.83E-06 2.25E-01 7.47E-01 0.102 -1.870 0.144 -0.019 0.139 0.236 0.154 0.222
3 131,537,570 rs3914307 0.185 INT CPNE4 4.87E-02 1.44E-03 7.98E-01 5.84E-01 1.99E-03 9.71E-01 1.91E-06 3.65E-01 7.53E-01 -0.014 -1.860 0.112 -0.019 0.126 0.237 0.135 0.222
3 131,537,647 rs4092640 0.191 INT CPNE4 8.25E-02 2.28E-03 6.53E-01 3.69E-01 2.03E-03 8.92E-01 2.00E-06 2.12E-01 7.53E-01 0.051 -1.860 0.147 -0.019 0.136 0.237 0.154 0.222
3 131,539,334 rs1026747 0.192 INT CPNE4 8.53E-02 2.29E-03 6.38E-01 3.78E-01 2.28E-03 8.95E-01 2.07E-06 2.20E-01 7.83E-01 0.050 -1.850 0.144 -0.017 0.136 0.238 0.155 0.223
3 131,541,210 rs16837878 0.185 INT CPNE4 5.39E-02 1.63E-03 7.78E-01 5.94E-01 2.52E-03 9.73E-01 2.46E-06 3.79E-01 7.91E-01 -0.013 -1.830 0.108 -0.016 0.126 0.237 0.136 0.221
3 131,543,767 rs6439319 0.192 INT CPNE4 6.79E-02 1.97E-03 7.12E-01 4.02E-01 1.62E-03 8.78E-01 1.30E-06 2.58E-01 7.40E-01 0.057 -1.890 0.131 -0.020 0.136 0.237 0.156 0.223
3 131,544,079 rs7648064 0.191 INT CPNE4 5.48E-02 1.07E-03 6.88E-01 4.90E-01 1.64E-03 9.46E-01 1.21E-06 2.43E-01 7.51E-01 -0.025 -1.900 0.137 -0.019 0.134 0.237 0.153 0.223
3 131,546,194 rs1464068 0.186 INT CPNE4 4.19E-02 1.25E-03 8.36E-01 6.03E-01 1.62E-03 9.97E-01 1.16E-06 4.11E-01 7.52E-01 -0.001 -1.900 0.100 -0.019 0.126 0.237 0.137 0.223
3 131,546,747 rs67051425 0.192 INT CPNE4 7.25E-02 1.97E-03 6.83E-01 3.80E-01 1.65E-03 8.67E-01 1.21E-06 2.39E-01 7.52E-01 0.063 -1.900 0.137 -0.019 0.136 0.237 0.156 0.223
3 131,551,585 rs61202912 0.192 INT CPNE4 7.22E-02 1.94E-03 6.81E-01 3.83E-01 1.66E-03 8.73E-01 1.21E-06 2.39E-01 7.54E-01 0.060 -1.900 0.138 -0.019 0.136 0.237 0.156 0.223
3 131,555,963 rs1606513 0.235 INT CPNE4 2.05E-02 1.00E-03 9.05E-01 7.07E-01 6.72E-04 8.72E-01 1.76E-06 4.32E-01 4.92E-01 -0.050 -1.860 0.078 -0.040 0.228 0.245 0.251 0.228
3 131,556,537 rs12639530 0.238 INT CPNE4 1.32E-02 5.97E-04 8.35E-01 8.94E-01 6.63E-04 7.21E-01 1.82E-06 5.20E-01 4.86E-01 -0.111 -1.850 0.063 -0.041 0.234 0.245 0.257 0.229
3 131,560,156 rs750048 0.192 INT CPNE4 7.61E-02 2.12E-03 6.76E-01 3.75E-01 1.77E-03 8.57E-01 1.33E-06 2.40E-01 7.62E-01 0.067 -1.890 0.137 -0.018 0.137 0.237 0.155 0.223
3 131,560,408 rs2077634 0.238 INT CPNE4 1.44E-02 6.56E-04 8.50E-01 8.91E-01 7.62E-04 7.34E-01 2.00E-06 5.30E-01 5.07E-01 -0.106 -1.840 0.062 -0.039 0.235 0.245 0.256 0.229
3 131,562,955 rs59025993 0.182 INT CPNE4 5.66E-02 2.02E-03 8.01E-01 5.57E-01 2.36E-03 8.68E-01 1.29E-06 4.70E-01 8.47E-01 0.065 -1.900 0.093 -0.012 0.121 0.236 0.125 0.222
3 131,563,467 rs7632654 0.191 INT CPNE4 8.96E-02 2.67E-03 6.47E-01 3.60E-01 2.30E-03 7.84E-01 1.32E-06 2.69E-01 8.37E-01 0.103 -1.890 0.130 -0.012 0.137 0.237 0.153 0.222
3 131,563,872 rs6763315 0.191 INT CPNE4 9.05E-02 2.68E-03 6.43E-01 3.60E-01 2.35E-03 7.84E-01 1.33E-06 2.69E-01 8.42E-01 0.103 -1.890 0.130 -0.012 0.137 0.237 0.153 0.223
3 131,563,898 rs6787747 0.196 INT CPNE4 7.33E-02 4.95E-03 8.78E-01 3.45E-01 1.38E-03 5.65E-01 1.03E-06 4.32E-01 7.22E-01 0.211 -1.890 0.092 -0.021 0.146 0.238 0.156 0.226
3 131,565,157 rs67078110 0.191 INT CPNE4 8.99E-02 2.68E-03 6.46E-01 3.60E-01 2.31E-03 7.83E-01 1.32E-06 2.69E-01 8.38E-01 0.103 -1.890 0.130 -0.012 0.137 0.237 0.153 0.222
3 131,565,742 rs66506820 0.185 INT CPNE4 5.35E-02 1.93E-03 8.17E-01 5.73E-01 2.27E-03 8.80E-01 1.27E-06 4.82E-01 8.38E-01 0.058 -1.890 0.087 -0.012 0.127 0.236 0.135 0.222
3 131,568,832 rs4854626 0.187 INT CPNE4 6.87E-02 2.40E-03 7.48E-01 4.84E-01 2.49E-03 8.19E-01 1.33E-06 4.11E-01 8.60E-01 0.088 -1.890 0.102 -0.011 0.130 0.237 0.135 0.223
3 131,569,008 rs4854627 0.202 INT CPNE4 5.60E-02 1.70E-03 7.70E-01 5.88E-01 2.64E-03 9.97E-01 2.27E-06 3.92E-01 8.14E-01 -0.001 -1.850 0.097 -0.014 0.161 0.238 0.173 0.224
22 46,189,190 rs136002 0.131 INT ATXN10 3.47E-04 2.19E-05 3.40E-01 6.71E-05 2.04E-01 2.16E-06 2.92E-01 6.04E-01 4.23E-01 -2.360 -0.494 -0.087 -0.051 0.064 0.166 0.071 0.186




Table A7. Top GWAS Results of Neuroticism Facet Depression Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
3 2,365,990 rs1145041 0.496 INT CNTN4 3.46E-03 3.23E-05 8.84E-01 4.81E-01 1.10E-03 1.66E-01 2.56E-06 5.67E-01 5.67E-01 0.425 1.810 -0.047 0.029 0.488 0.494 0.479 0.512
3 2,382,995 rs1627079 0.484 INT CNTN4 1.39E-03 4.32E-05 5.63E-01 3.99E-01 4.55E-04 2.01E-01 2.32E-06 8.21E-01 3.90E-01 -0.400 -1.810 0.019 -0.043 0.490 0.485 0.505 0.468
3 2,384,639 rs1666326 0.491 INT CNTN4 1.25E-03 8.74E-06 7.71E-01 3.17E-01 6.57E-04 6.00E-02 4.62E-06 4.79E-01 4.00E-01 0.589 1.760 -0.059 0.042 0.448 0.513 0.443 0.532
3 2,385,167 rs1720179 0.491 INT CNTN4 1.26E-03 8.92E-06 7.69E-01 3.17E-01 6.59E-04 6.01E-02 4.75E-06 4.79E-01 3.98E-01 0.589 1.760 -0.059 0.042 0.449 0.513 0.443 0.532
3 2,385,295 rs1685491 0.483 INT CNTN4 1.39E-03 4.21E-05 5.66E-01 3.95E-01 4.66E-04 1.98E-01 2.33E-06 8.23E-01 3.94E-01 -0.403 -1.810 0.018 -0.043 0.489 0.485 0.505 0.468
3 2,385,305 rs4685515 0.363 INT CNTN4 1.25E-02 3.30E-04 9.31E-01 8.70E-01 1.53E-03 4.19E-01 6.75E-06 4.69E-01 5.45E-01 -0.291 -1.750 0.065 -0.031 0.274 0.437 0.276 0.426
3 2,385,988 rs12639121 0.365 INT CNTN4 1.17E-02 3.24E-04 9.07E-01 8.59E-01 1.42E-03 4.30E-01 5.90E-06 4.98E-01 5.42E-01 -0.282 -1.760 0.060 -0.031 0.277 0.437 0.281 0.426
3 2,386,340 rs1685492 0.483 INT CNTN4 1.40E-03 4.22E-05 5.67E-01 3.94E-01 4.72E-04 1.98E-01 2.34E-06 8.24E-01 3.96E-01 -0.403 -1.810 0.018 -0.042 0.489 0.485 0.505 0.468
3 2,386,988 rs1554562 0.489 INT CNTN4 1.48E-03 1.32E-05 7.57E-01 3.61E-01 6.23E-04 8.09E-02 4.25E-06 4.95E-01 3.97E-01 0.550 1.770 -0.057 0.042 0.446 0.511 0.438 0.530
3 2,387,439 rs1566382 0.483 INT CNTN4 1.47E-03 3.85E-05 5.95E-01 4.05E-01 4.81E-04 1.88E-01 2.35E-06 7.74E-01 3.99E-01 -0.413 -1.810 0.024 -0.042 0.489 0.485 0.505 0.468
3 2,387,692 rs3856836 0.364 INT CNTN4 1.26E-02 2.21E-04 9.93E-01 8.50E-01 1.66E-03 3.99E-01 3.90E-06 4.68E-01 6.24E-01 -0.304 -1.790 0.065 -0.025 0.274 0.438 0.277 0.428
3 2,387,815 rs1666329 0.483 INT CNTN4 1.42E-03 4.24E-05 5.70E-01 3.94E-01 4.82E-04 1.98E-01 2.36E-06 8.24E-01 3.99E-01 -0.404 -1.810 0.018 -0.042 0.489 0.485 0.505 0.468
3 2,387,835 rs3856838 0.490 INT CNTN4 3.55E-03 9.60E-05 7.11E-01 4.44E-01 1.37E-03 2.17E-01 7.21E-06 7.68E-01 5.13E-01 -0.386 -1.740 0.024 -0.033 0.493 0.495 0.506 0.478
3 2,388,521 rs1617892 0.484 INT CNTN4 1.02E-03 2.96E-05 5.35E-01 3.99E-01 2.91E-04 2.00E-01 1.23E-06 8.19E-01 3.62E-01 -0.401 -1.860 0.019 -0.046 0.488 0.487 0.505 0.470
3 2,389,325 rs2728517 0.472 INT CNTN4 1.78E-04 2.79E-06 4.36E-01 1.07E-01 3.64E-04 3.89E-02 2.20E-06 9.75E-01 3.55E-01 0.663 1.820 0.003 0.046 0.413 0.507 0.401 0.527
3 2,390,612 rs1685495 0.483 INT CNTN4 1.50E-03 3.96E-05 5.96E-01 3.96E-01 5.19E-04 1.85E-01 2.59E-06 7.85E-01 4.05E-01 -0.413 -1.800 0.022 -0.042 0.489 0.485 0.505 0.468
3 2,391,098 rs4684343 0.368 INT CNTN4 9.47E-03 1.93E-04 9.26E-01 7.83E-01 1.37E-03 3.50E-01 4.98E-06 4.83E-01 5.50E-01 -0.334 -1.780 0.063 -0.031 0.285 0.438 0.286 0.426
3 2,392,644 rs968057 0.484 INT CNTN4 3.43E-04 1.95E-05 3.50E-01 1.29E-01 6.10E-04 1.17E-01 3.01E-06 6.29E-01 4.23E-01 0.494 1.790 0.039 0.040 0.437 0.511 0.424 0.531
3 2,392,718 rs4685517 0.458 INT CNTN4 2.83E-04 3.10E-06 5.22E-01 8.90E-02 8.56E-04 2.62E-02 6.10E-06 9.81E-01 4.27E-01 0.709 1.740 -0.002 0.040 0.375 0.509 0.372 0.530
3 3,655,219 rs9868273 0.382 . . 1.11E-02 3.18E-03 4.63E-01 4.42E-01 6.98E-03 8.62E-01 3.44E-06 1.56E-01 9.31E-01 -0.052 1.930 0.125 -0.005 0.376 0.378 0.367 0.396
3 3,655,838 rs766219 0.251 . . 1.32E-02 2.04E-03 5.98E-01 3.11E-01 1.62E-02 9.55E-01 2.43E-06 9.65E-02 6.13E-01 -0.030 2.020 0.231 -0.027 0.098 0.341 0.111 0.375
4 21,367,902 rs1390259 0.083 INT KCNIP4 2.34E-01 9.89E-03 4.49E-01 6.95E-01 2.16E-01 5.61E-01 5.49E-06 1.86E-01 6.67E-02 -0.288 3.410 0.198 -0.169 0.098 0.068 0.111 0.067
4 21,368,339 rs2323001 0.098 INT KCNIP4 4.44E-01 1.08E-02 1.91E-01 7.05E-01 4.93E-01 5.39E-01 5.72E-06 1.80E-01 1.19E-02 -0.282 3.030 0.193 -0.208 0.114 0.085 0.123 0.082
4 21,377,097 rs1994983 0.113 INT KCNIP4 1.93E-01 8.18E-04 1.90E-01 2.75E-01 4.37E-01 6.73E-01 4.89E-06 2.28E-01 1.53E-02 0.176 3.030 0.148 -0.198 0.143 0.089 0.159 0.082




Table A8. Top GWAS Results of Neuroticism Facet Hostility Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
5 6,605,271 rs506416 0.239 INT NSUN2 1.63E-05 1.84E-07 2.90E-01 5.55E-04 6.75E-03 1.69E-05 2.63E-03 8.35E-01 2.54E-01 -1.920 -1.280 -0.025 -0.059 0.137 0.293 0.140 0.328
5 6,608,534 rs502272 0.239 INT NSUN2 2.13E-05 1.91E-07 3.26E-01 6.51E-04 7.65E-03 1.75E-05 2.64E-03 8.81E-01 2.76E-01 -1.920 -1.270 -0.018 -0.057 0.136 0.293 0.138 0.329




Table A9. Top GWAS Results of Neuroticism Facet Impulsiveness Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
6 118,554,463 rs9489325 0.098 INT SLC35F1 2.94E-03 3.98E-06 8.37E-01 5.38E-04 3.53E-01 6.10E-06 6.42E-02 9.63E-01 8.28E-01 1.890 1.270 -0.006 -0.022 0.130 0.078 0.137 0.067
6 118,555,555 rs928599 0.097 INT SLC35F1 3.98E-03 4.24E-06 7.48E-01 8.67E-04 3.59E-01 6.16E-06 6.67E-02 8.03E-01 8.27E-01 1.890 1.260 -0.032 -0.022 0.130 0.078 0.133 0.067
6 118,555,615 rs928598 0.097 INT SLC35F1 4.06E-03 4.44E-06 7.48E-01 8.96E-04 3.59E-01 6.51E-06 6.69E-02 8.03E-01 8.27E-01 1.880 1.260 -0.032 -0.022 0.130 0.078 0.133 0.067
12 81,927,644 rs7304553 0.111 INT PPFIA2 1.02E-02 9.66E-07 3.08E-01 1.82E-02 1.77E-01 6.70E-05 3.89E-03 2.61E-01 6.43E-01 -1.710 -1.570 0.159 0.036 0.104 0.115 0.098 0.120
12 81,927,864 rs7315394 0.111 INT PPFIA2 8.63E-03 9.78E-07 3.47E-01 1.47E-02 1.75E-01 6.79E-05 3.89E-03 3.19E-01 6.50E-01 -1.710 -1.570 0.140 0.035 0.104 0.115 0.098 0.120
12 81,944,088 rs17008693 0.118 INT PPFIA2 4.07E-03 2.54E-07 3.99E-01 6.41E-03 1.51E-01 3.93E-05 1.73E-03 4.82E-01 5.90E-01 -1.790 -1.650 0.093 0.041 0.108 0.122 0.116 0.125
12 81,948,660 rs17008707 0.115 INT PPFIA2 4.16E-03 1.65E-07 3.54E-01 6.87E-03 1.48E-01 2.56E-05 1.67E-03 3.91E-01 5.94E-01 -1.840 -1.660 0.118 0.041 0.102 0.121 0.109 0.125
12 81,953,738 rs74106644 0.118 INT PPFIA2 3.76E-03 2.19E-07 4.04E-01 6.23E-03 1.45E-01 3.64E-05 1.61E-03 4.78E-01 6.00E-01 -1.800 -1.660 0.094 0.040 0.107 0.121 0.117 0.125
12 81,956,398 rs12424207 0.103 INT PPFIA2 7.65E-03 2.01E-07 2.45E-01 1.37E-02 1.64E-01 9.29E-05 6.08E-04 3.85E-01 4.16E-01 -1.730 -2.080 0.119 0.072 0.103 0.098 0.113 0.101
12 81,960,411 rs17008729 0.116 INT PPFIA2 3.70E-03 1.42E-07 3.67E-01 5.95E-03 1.46E-01 1.99E-05 1.80E-03 3.94E-01 6.12E-01 -1.870 -1.640 0.117 0.039 0.101 0.121 0.109 0.126
12 81,961,143 rs79946680 0.118 INT PPFIA2 4.12E-03 2.57E-07 3.98E-01 7.00E-03 1.46E-01 3.84E-05 1.79E-03 4.50E-01 6.13E-01 -1.800 -1.640 0.100 0.039 0.106 0.121 0.117 0.126
12 81,964,035 rs74106657 0.118 INT PPFIA2 4.13E-03 2.48E-07 3.94E-01 7.35E-03 1.42E-01 3.82E-05 1.74E-03 4.34E-01 6.20E-01 -1.800 -1.650 0.103 0.038 0.106 0.121 0.117 0.126
12 81,968,978 rs74106658 0.119 INT PPFIA2 4.38E-03 2.44E-07 3.78E-01 8.34E-03 1.39E-01 4.11E-05 1.60E-03 4.07E-01 6.18E-01 -1.790 -1.660 0.109 0.038 0.107 0.121 0.118 0.126
12 81,970,885 rs1955385 0.123 INT PPFIA2 2.84E-03 2.06E-07 4.68E-01 8.90E-03 9.31E-02 4.76E-05 1.19E-03 4.11E-01 7.53E-01 -1.760 -1.680 0.108 0.024 0.108 0.128 0.121 0.132
12 81,973,345 rs74106663 0.119 INT PPFIA2 4.29E-03 2.23E-07 3.75E-01 8.59E-03 1.34E-01 4.05E-05 1.49E-03 3.96E-01 6.22E-01 -1.790 -1.670 0.112 0.038 0.107 0.121 0.118 0.126
12 82,003,495 rs1955383 0.110 INT PPFIA2 5.66E-03 9.26E-08 2.47E-01 1.37E-02 1.28E-01 2.09E-05 1.15E-03 1.98E-01 6.04E-01 -1.960 -1.720 0.189 0.039 0.088 0.120 0.096 0.126
15 47,895,543 rs1224671 0.234 INT SEMA6D 2.50E-06 3.37E-06 3.39E-02 1.41E-04 3.42E-03 2.31E-06 9.38E-02 8.00E-01 1.63E-02 -1.870 -0.624 -0.029 -0.136 0.132 0.313 0.144 0.305




Table A10. Top GWAS Results of Neuroticism Facet Self-consciousness Meta-analyzed with Results from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
3 131,536,441 rs61564665 0.176 INT CPNE4 5.64E-03 2.07E-04 7.30E-01 4.65E-01 2.40E-03 3.30E-01 6.95E-06 9.73E-01 6.58E-01 -0.420 -2.000 0.004 -0.028 0.136 0.210 0.145 0.201
3 131,536,917 rs16837870 0.192 INT CPNE4 4.52E-02 6.35E-04 6.72E-01 6.22E-01 2.03E-03 7.18E-01 2.11E-06 2.25E-01 7.47E-01 -0.153 -2.050 0.144 -0.019 0.139 0.236 0.154 0.222
3 131,537,570 rs3914307 0.185 INT CPNE4 2.28E-02 2.76E-04 7.98E-01 9.46E-01 2.08E-03 5.10E-01 2.14E-06 3.65E-01 7.53E-01 -0.292 -2.040 0.112 -0.019 0.126 0.237 0.135 0.222
3 131,537,647 rs4092640 0.191 INT CPNE4 3.82E-02 3.88E-04 6.53E-01 7.07E-01 2.09E-03 5.88E-01 2.16E-06 2.12E-01 7.53E-01 -0.233 -2.040 0.147 -0.019 0.136 0.237 0.154 0.222
3 131,539,334 rs1026747 0.192 INT CPNE4 4.05E-02 4.09E-04 6.38E-01 7.15E-01 2.40E-03 5.91E-01 2.34E-06 2.20E-01 7.83E-01 -0.230 -2.030 0.144 -0.017 0.136 0.238 0.155 0.223
3 131,541,210 rs16837878 0.185 INT CPNE4 2.58E-02 3.24E-04 7.78E-01 9.55E-01 2.65E-03 5.15E-01 2.79E-06 3.79E-01 7.91E-01 -0.288 -2.010 0.108 -0.016 0.126 0.237 0.136 0.221
3 131,543,767 rs6439319 0.192 INT CPNE4 3.20E-02 3.63E-04 7.12E-01 7.45E-01 1.76E-03 6.10E-01 1.59E-06 2.58E-01 7.40E-01 -0.219 -2.080 0.131 -0.020 0.136 0.237 0.156 0.223
3 131,544,079 rs7648064 0.191 INT CPNE4 2.93E-02 2.60E-04 6.88E-01 7.97E-01 1.85E-03 5.29E-01 1.62E-06 2.43E-01 7.51E-01 -0.271 -2.080 0.137 -0.019 0.134 0.237 0.153 0.223
3 131,546,194 rs1464068 0.186 INT CPNE4 2.05E-02 2.67E-04 8.36E-01 9.68E-01 1.87E-03 5.32E-01 1.66E-06 4.11E-01 7.52E-01 -0.278 -2.070 0.100 -0.019 0.126 0.237 0.137 0.223
3 131,546,747 rs67051425 0.192 INT CPNE4 3.48E-02 3.72E-04 6.83E-01 7.23E-01 1.88E-03 6.09E-01 1.68E-06 2.39E-01 7.52E-01 -0.220 -2.070 0.137 -0.019 0.136 0.237 0.156 0.223
3 131,551,585 rs61202912 0.192 INT CPNE4 3.52E-02 3.78E-04 6.81E-01 7.23E-01 1.92E-03 6.09E-01 1.73E-06 2.39E-01 7.54E-01 -0.220 -2.070 0.138 -0.019 0.136 0.237 0.156 0.223
3 131,555,963 rs1606513 0.235 INT CPNE4 4.98E-03 5.93E-05 9.05E-01 6.41E-01 9.03E-04 2.11E-01 3.44E-06 4.32E-01 4.92E-01 -0.420 -1.990 0.078 -0.040 0.228 0.245 0.251 0.228
3 131,556,537 rs12639530 0.238 INT CPNE4 3.84E-03 5.32E-05 8.35E-01 5.57E-01 8.89E-04 1.97E-01 3.54E-06 5.20E-01 4.86E-01 -0.428 -1.990 0.063 -0.041 0.234 0.245 0.257 0.229
3 131,560,156 rs750048 0.192 INT CPNE4 3.40E-02 3.40E-04 6.76E-01 7.48E-01 1.99E-03 5.81E-01 1.76E-06 2.40E-01 7.62E-01 -0.237 -2.070 0.137 -0.018 0.137 0.237 0.155 0.223
3 131,560,408 rs2077634 0.238 INT CPNE4 4.01E-03 5.33E-05 8.50E-01 5.52E-01 9.72E-04 1.98E-01 3.49E-06 5.30E-01 5.07E-01 -0.427 -1.990 0.062 -0.039 0.235 0.245 0.256 0.229
3 131,562,955 rs59025993 0.182 INT CPNE4 3.07E-02 5.37E-04 8.01E-01 8.88E-01 2.80E-03 6.80E-01 2.00E-06 4.70E-01 8.47E-01 -0.190 -2.060 0.093 -0.012 0.121 0.236 0.125 0.222
3 131,563,467 rs7632654 0.191 INT CPNE4 3.82E-02 3.75E-04 6.47E-01 7.62E-01 2.58E-03 6.04E-01 1.77E-06 2.69E-01 8.37E-01 -0.221 -2.070 0.130 -0.012 0.137 0.237 0.153 0.222
3 131,563,872 rs6763315 0.191 INT CPNE4 3.86E-02 3.76E-04 6.43E-01 7.61E-01 2.63E-03 6.05E-01 1.77E-06 2.69E-01 8.42E-01 -0.221 -2.070 0.130 -0.012 0.137 0.237 0.153 0.223
3 131,563,898 rs6787747 0.196 INT CPNE4 2.42E-02 4.75E-04 8.78E-01 8.88E-01 1.85E-03 6.42E-01 2.10E-06 4.32E-01 7.22E-01 -0.192 -2.030 0.092 -0.021 0.146 0.238 0.156 0.226
3 131,565,157 rs67078110 0.191 INT CPNE4 3.83E-02 3.75E-04 6.46E-01 7.61E-01 2.59E-03 6.05E-01 1.76E-06 2.69E-01 8.38E-01 -0.221 -2.070 0.130 -0.012 0.137 0.237 0.153 0.222
3 131,565,742 rs66506820 0.185 INT CPNE4 2.23E-02 2.90E-04 8.17E-01 9.83E-01 2.59E-03 5.44E-01 1.76E-06 4.82E-01 8.38E-01 -0.268 -2.070 0.087 -0.012 0.127 0.236 0.135 0.222
3 131,568,832 rs4854626 0.187 INT CPNE4 3.41E-02 5.09E-04 7.48E-01 8.20E-01 2.63E-03 7.02E-01 1.52E-06 4.11E-01 8.60E-01 -0.171 -2.080 0.102 -0.011 0.130 0.237 0.135 0.223
3 131,569,008 rs4854627 0.202 INT CPNE4 1.99E-02 1.74E-04 7.70E-01 8.68E-01 3.25E-03 3.57E-01 3.84E-06 3.92E-01 8.14E-01 -0.375 -2.010 0.097 -0.014 0.161 0.238 0.173 0.224
5 121,532,284 rs12654712 0.185 . . 9.05E-03 1.22E-03 5.69E-01 7.42E-01 1.50E-03 9.96E-01 1.12E-06 6.09E-01 7.34E-01 0.002 2.280 0.060 0.022 0.169 0.197 0.163 0.201
5 121,534,579 rs17433546 0.180 . . 1.13E-02 7.60E-04 7.30E-01 6.43E-01 3.09E-03 7.69E-01 2.09E-06 7.10E-01 8.71E-01 0.122 2.160 0.048 0.010 0.130 0.206 0.129 0.225
5 121,534,822 rs10519700 0.251 . . 1.25E-02 8.53E-03 3.30E-01 9.20E-01 1.25E-03 3.89E-01 7.92E-07 2.29E-01 7.24E-01 -0.269 2.190 0.109 0.022 0.295 0.216 0.277 0.228
5 121,535,090 rs35695438 0.291 . . 1.51E-02 2.47E-03 6.07E-01 9.69E-01 1.13E-03 6.92E-01 5.43E-07 6.75E-01 7.37E-01 -0.121 2.190 0.037 0.021 0.387 0.221 0.356 0.230
5 121,535,139 rs1421883 0.248 . . 1.02E-02 7.92E-03 2.95E-01 7.88E-01 1.50E-03 4.12E-01 8.27E-07 1.56E-01 7.69E-01 -0.254 2.180 0.131 0.018 0.294 0.216 0.272 0.221




Table A11. Top GWAS Results of Neuroticism Facet Vulnerability to Stress Meta-analyzed with Results from GWAS of CaD.  
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
1 234,107,275 rs6702481 0.412 INT SLC35F3 9.08E-04 8.94E-08 6.78E-01 7.12E-04 1.47E-01 2.74E-05 8.70E-04 8.16E-01 5.06E-01 1.810 1.680 0.019 -0.037 0.519 0.342 0.545 0.313
1 234,107,883 rs11587514 0.413 INT SLC35F3 8.02E-04 8.65E-08 7.09E-01 5.74E-04 1.48E-01 2.64E-05 8.72E-04 7.53E-01 5.02E-01 1.810 1.680 0.026 -0.037 0.519 0.342 0.547 0.313
1 234,108,633 rs12567347 0.409 INT SLC35F3 9.36E-04 1.30E-07 7.16E-01 7.22E-04 1.49E-01 4.02E-05 8.84E-04 7.39E-01 5.02E-01 1.810 1.680 0.028 -0.037 0.512 0.342 0.538 0.313
1 234,110,769 rs12047995 0.396 INT SLC35F3 5.69E-05 3.55E-08 6.93E-01 1.04E-04 5.04E-02 2.10E-05 4.48E-04 3.47E-01 8.66E-01 1.910 1.790 0.079 -0.009 0.531 0.303 0.559 0.276
1 234,116,698 rs4279910 0.336 INT SLC35F3 4.10E-04 1.15E-06 7.47E-01 2.54E-04 1.34E-01 2.23E-05 1.08E-02 5.44E-01 9.79E-01 1.970 1.370 0.053 -0.002 0.393 0.302 0.417 0.276
1 234,116,713 rs4362043 0.336 INT SLC35F3 4.08E-04 1.16E-06 7.44E-01 2.54E-04 1.34E-01 2.26E-05 1.08E-02 5.42E-01 9.81E-01 1.970 1.370 0.054 -0.001 0.393 0.302 0.417 0.276
3 131,536,289 rs60078694 0.172 INT CPNE4 3.84E-02 2.52E-03 9.74E-01 7.39E-01 2.40E-03 9.15E-01 2.95E-06 6.94E-01 7.56E-01 0.071 -2.680 0.049 -0.020 0.132 0.207 0.138 0.198
3 131,536,441 rs61564665 0.176 INT CPNE4 3.04E-03 6.33E-05 7.30E-01 3.59E-01 1.73E-03 2.24E-01 3.18E-06 9.73E-01 6.58E-01 -0.791 -2.640 0.004 -0.028 0.136 0.210 0.145 0.201
3 131,536,917 rs16837870 0.192 INT CPNE4 5.21E-02 8.79E-04 6.72E-01 5.35E-01 1.83E-03 8.44E-01 1.64E-06 2.25E-01 7.47E-01 -0.129 -2.690 0.144 -0.019 0.139 0.236 0.154 0.222
3 131,537,570 rs3914307 0.185 INT CPNE4 3.28E-02 6.09E-04 7.98E-01 7.54E-01 1.91E-03 7.34E-01 1.72E-06 3.65E-01 7.53E-01 -0.230 -2.680 0.112 -0.019 0.126 0.237 0.135 0.222
3 131,537,647 rs4092640 0.191 INT CPNE4 5.15E-02 7.72E-04 6.53E-01 5.58E-01 1.98E-03 7.87E-01 1.89E-06 2.12E-01 7.53E-01 -0.179 -2.670 0.147 -0.019 0.136 0.237 0.154 0.222
3 131,539,334 rs1026747 0.192 INT CPNE4 5.22E-02 7.37E-04 6.38E-01 5.62E-01 2.07E-03 7.95E-01 1.62E-06 2.20E-01 7.83E-01 -0.172 -2.680 0.144 -0.017 0.136 0.238 0.155 0.223
3 131,541,210 rs16837878 0.185 INT CPNE4 3.57E-02 6.61E-04 7.78E-01 7.63E-01 2.30E-03 7.38E-01 1.97E-06 3.79E-01 7.91E-01 -0.225 -2.660 0.108 -0.016 0.126 0.237 0.136 0.221
3 131,543,767 rs6439319 0.192 INT CPNE4 3.97E-02 5.88E-04 7.12E-01 6.43E-01 1.74E-03 7.40E-01 1.53E-06 2.58E-01 7.40E-01 -0.220 -2.710 0.131 -0.020 0.136 0.237 0.156 0.223
3 131,544,079 rs7648064 0.191 INT CPNE4 3.45E-02 3.75E-04 6.88E-01 7.20E-01 1.82E-03 6.19E-01 1.57E-06 2.43E-01 7.51E-01 -0.331 -2.710 0.137 -0.019 0.134 0.237 0.153 0.223
3 131,546,194 rs1464068 0.186 INT CPNE4 2.75E-02 5.05E-04 8.36E-01 8.18E-01 1.78E-03 7.05E-01 1.46E-06 4.11E-01 7.52E-01 -0.256 -2.720 0.100 -0.019 0.126 0.237 0.137 0.223
3 131,546,747 rs67051425 0.192 INT CPNE4 4.42E-02 6.42E-04 6.83E-01 6.09E-01 1.85E-03 7.58E-01 1.60E-06 2.39E-01 7.52E-01 -0.204 -2.710 0.137 -0.019 0.136 0.237 0.156 0.223
3 131,551,585 rs61202912 0.192 INT CPNE4 4.44E-02 6.42E-04 6.81E-01 6.13E-01 1.89E-03 7.53E-01 1.66E-06 2.39E-01 7.54E-01 -0.208 -2.700 0.138 -0.019 0.136 0.237 0.156 0.223
3 131,555,963 rs1606513 0.235 INT CPNE4 5.40E-03 6.98E-05 9.05E-01 9.56E-01 2.70E-04 4.72E-01 2.17E-07 4.32E-01 4.92E-01 -0.381 -2.880 0.078 -0.040 0.228 0.245 0.251 0.228
3 131,556,537 rs12639530 0.238 INT CPNE4 3.07E-03 3.40E-05 8.35E-01 7.51E-01 2.60E-04 3.47E-01 2.13E-07 5.20E-01 4.86E-01 -0.491 -2.880 0.063 -0.041 0.234 0.245 0.257 0.229
3 131,560,156 rs750048 0.192 INT CPNE4 4.74E-02 7.24E-04 6.76E-01 5.94E-01 1.97E-03 7.81E-01 1.73E-06 2.40E-01 7.62E-01 -0.183 -2.700 0.137 -0.018 0.137 0.237 0.155 0.223
3 131,560,408 rs2077634 0.238 INT CPNE4 3.28E-03 3.57E-05 8.50E-01 7.49E-01 2.94E-04 3.51E-01 2.22E-07 5.30E-01 5.07E-01 -0.487 -2.870 0.062 -0.039 0.235 0.245 0.256 0.229
3 131,562,955 rs59025993 0.182 INT CPNE4 6.70E-02 2.91E-03 8.01E-01 5.29E-01 2.90E-03 8.26E-01 2.18E-06 4.70E-01 8.47E-01 0.156 -2.680 0.093 -0.012 0.121 0.236 0.125 0.222
3 131,563,467 rs7632654 0.191 INT CPNE4 5.69E-02 9.41E-04 6.47E-01 5.90E-01 2.74E-03 8.32E-01 2.06E-06 2.69E-01 8.37E-01 -0.140 -2.680 0.130 -0.012 0.137 0.237 0.153 0.222
3 131,563,872 rs6763315 0.191 INT CPNE4 5.74E-02 9.41E-04 6.43E-01 5.90E-01 2.79E-03 8.32E-01 2.06E-06 2.69E-01 8.42E-01 -0.140 -2.680 0.130 -0.012 0.137 0.237 0.153 0.223
3 131,563,898 rs6787747 0.196 INT CPNE4 3.91E-02 1.32E-03 8.78E-01 6.98E-01 2.11E-03 8.85E-01 2.89E-06 4.32E-01 7.22E-01 -0.093 -2.620 0.092 -0.021 0.146 0.238 0.156 0.226
3 131,565,157 rs67078110 0.191 INT CPNE4 5.70E-02 9.41E-04 6.46E-01 5.90E-01 2.75E-03 8.32E-01 2.06E-06 2.69E-01 8.38E-01 -0.140 -2.680 0.130 -0.012 0.137 0.237 0.153 0.222
3 131,565,742 rs66506820 0.185 INT CPNE4 3.72E-02 8.80E-04 8.17E-01 7.83E-01 2.67E-03 8.24E-01 1.90E-06 4.82E-01 8.38E-01 -0.150 -2.690 0.087 -0.012 0.127 0.236 0.135 0.222
3 131,568,832 rs4854626 0.187 INT CPNE4 4.81E-02 1.09E-03 7.48E-01 6.72E-01 2.78E-03 8.98E-01 1.75E-06 4.11E-01 8.60E-01 -0.087 -2.700 0.102 -0.011 0.130 0.237 0.135 0.223
13 101,436,664 rs1158451 0.099 INT NALCN-AS1 3.67E-02 1.34E-06 1.07E-01 1.64E-01 1.19E-01 4.58E-02 4.82E-07 8.15E-01 7.24E-02 1.460 3.910 -0.030 -0.141 0.096 0.099 0.100 0.102
13 101,439,553 rs912368 0.100 INT NALCN-AS1 3.46E-02 1.00E-06 1.03E-01 1.52E-01 1.20E-01 4.01E-02 4.25E-07 8.10E-01 6.91E-02 1.470 3.910 -0.031 -0.143 0.098 0.098 0.101 0.102
13 101,443,040 rs77516719 0.091 INT NALCN-AS1 5.79E-02 4.03E-06 9.54E-02 2.53E-01 1.28E-01 9.12E-02 4.56E-07 8.00E-01 6.41E-02 1.340 3.910 -0.036 -0.144 0.079 0.098 0.079 0.102
13 101,443,896 rs1983323 0.091 INT NALCN-AS1 5.37E-02 3.30E-06 9.66E-02 2.36E-01 1.27E-01 8.08E-02 4.60E-07 7.98E-01 6.54E-02 1.400 3.900 -0.036 -0.144 0.076 0.099 0.079 0.102
13 101,444,140 rs912371 0.091 INT NALCN-AS1 5.81E-02 4.28E-06 9.71E-02 2.57E-01 1.27E-01 9.33E-02 4.72E-07 7.98E-01 6.59E-02 1.340 3.910 -0.036 -0.143 0.079 0.098 0.079 0.102
13 101,447,275 rs7337962 0.091 INT NALCN-AS1 7.44E-02 2.43E-06 5.53E-02 3.28E-01 1.30E-01 6.37E-02 5.31E-07 4.77E-01 6.61E-02 1.480 3.890 -0.096 -0.143 0.076 0.098 0.084 0.102
13 101,447,967 rs4772330 0.092 INT NALCN-AS1 6.17E-02 2.27E-06 6.96E-02 2.58E-01 1.35E-01 6.10E-02 5.32E-07 6.20E-01 6.25E-02 1.490 3.900 -0.067 -0.145 0.079 0.098 0.085 0.102
13 101,448,466 rs6491581 0.107 INT NALCN-AS1 5.59E-02 8.12E-07 5.18E-02 2.14E-01 1.46E-01 4.45E-02 2.35E-07 6.27E-01 4.26E-02 1.540 3.960 -0.066 -0.155 0.094 0.113 0.095 0.119
13 101,448,738 rs6491582 0.091 INT NALCN-AS1 4.74E-02 1.88E-06 9.02E-02 2.37E-01 1.10E-01 5.71E-02 4.68E-07 6.54E-01 8.02E-02 1.510 3.930 -0.062 -0.138 0.079 0.097 0.084 0.100
13 101,451,472 rs4771372 0.101 INT NALCN-AS1 7.80E-02 1.06E-06 3.58E-02 2.78E-01 1.64E-01 3.81E-02 5.24E-07 4.17E-01 4.65E-02 1.500 3.880 -0.101 -0.155 0.098 0.098 0.108 0.101
13 101,453,076 rs1853555 0.095 INT . 1.45E-01 1.16E-05 3.96E-02 5.65E-01 1.52E-01 1.64E-01 4.63E-07 4.33E-01 5.01E-02 1.060 3.920 -0.106 -0.152 0.087 0.098 0.089 0.101
13 101,453,397 rs2093797 0.092 INT NALCN-AS1 6.96E-02 1.91E-06 5.48E-02 2.56E-01 1.56E-01 5.51E-02 5.27E-07 5.87E-01 5.02E-02 1.520 3.910 -0.076 -0.152 0.079 0.097 0.084 0.101
13 101,455,716 rs8001939 0.102 INT . 4.81E-02 1.07E-05 1.71E-01 3.64E-01 6.72E-02 1.14E-01 1.20E-06 6.24E-01 1.85E-01 1.180 3.590 -0.063 -0.101 0.090 0.107 0.097 0.109
13 101,456,163 rs7139965 0.101 INT . 4.00E-02 1.06E-05 2.06E-01 3.61E-01 5.39E-02 1.17E-01 1.11E-06 6.42E-01 2.24E-01 1.170 3.610 -0.059 -0.093 0.090 0.107 0.098 0.107
13 101,457,062 rs2147096 0.103 INT . 3.16E-02 1.81E-05 3.05E-01 2.54E-01 6.31E-02 1.34E-01 1.81E-06 9.79E-01 2.19E-01 1.090 3.530 -0.003 -0.094 0.094 0.107 0.105 0.107
13 101,457,472 rs4771374 0.103 INT . 3.01E-02 1.68E-05 3.10E-01 2.68E-01 5.59E-02 1.45E-01 1.27E-06 9.79E-01 2.24E-01 1.070 3.580 -0.003 -0.093 0.093 0.107 0.105 0.107
13 101,457,546 rs4771375 0.096 INT . 6.86E-02 1.30E-05 1.23E-01 3.19E-01 1.22E-01 1.71E-01 4.91E-07 9.25E-01 7.06E-02 1.010 3.920 -0.013 -0.142 0.091 0.098 0.098 0.098
13 101,458,912 rs9518178 0.113 INT NALCN-AS1 2.19E-02 4.17E-06 2.61E-01 2.43E-01 4.31E-02 6.04E-02 1.43E-06 6.57E-01 2.89E-01 1.290 3.530 -0.051 -0.081 0.111 0.108 0.128 0.110
13 101,459,414 rs4772334 0.107 INT . 1.99E-02 7.87E-06 3.41E-01 2.34E-01 4.03E-02 9.24E-02 1.31E-06 8.64E-01 2.99E-01 1.230 3.560 -0.021 -0.080 0.097 0.108 0.114 0.110
13 101,459,509 rs4771376 0.112 INT NALCN-AS1 2.45E-02 5.53E-06 2.60E-01 2.75E-01 4.22E-02 7.17E-02 1.45E-06 6.40E-01 2.95E-01 1.240 3.530 -0.054 -0.080 0.110 0.108 0.128 0.109
13 101,460,534 rs2181726 0.096 INT . 6.05E-02 1.03E-05 1.31E-01 3.76E-01 8.57E-02 1.45E-01 5.57E-07 7.07E-01 1.15E-01 1.100 3.900 -0.050 -0.124 0.089 0.098 0.097 0.100
13 101,461,657 rs4771378 0.214 INT . 1.17E-01 4.29E-04 2.66E-01 9.41E-01 3.20E-02 7.27E-01 8.85E-07 5.89E-01 3.28E-01 0.159 3.500 -0.047 -0.074 0.344 0.119 0.346 0.112
13 101,461,945 rs4771379 0.214 INT . 1.16E-01 4.22E-04 2.66E-01 9.43E-01 3.19E-02 7.22E-01 8.89E-07 5.86E-01 3.29E-01 0.162 3.500 -0.047 -0.075 0.344 0.119 0.346 0.112
13 101,462,514 rs6491585 0.174 INT . 2.64E-01 1.03E-03 1.32E-01 6.55E-01 6.15E-02 8.08E-01 2.96E-06 3.18E-01 2.54E-01 0.118 3.360 -0.095 -0.088 0.266 0.115 0.243 0.110
13 101,462,664 rs1924278 0.093 INT . 1.44E-01 3.51E-05 6.80E-02 8.43E-01 7.74E-02 2.69E-01 6.00E-07 3.03E-01 1.32E-01 0.843 3.900 -0.149 -0.120 0.086 0.098 0.084 0.099




“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 





Table A12. Top GWAS Results of Bivariate AA Analyses for All Neuroticism Domains and Facets Meta-analyzed with Results 
from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
  
Trait Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
Depression 3 54,343,019 rs6445646 0.167 INT CACNA2D3 9.36E-04 1.00E-02 3.34E-02 4.93E-06 6.83E-01 6.12E-05 5.22E-01 2.04E-02 3.25E-01 -1.490 0.340 -0.231 -0.067 0.178 0.152 0.190 0.157
Depression 5 116,019,417 rs10072088 0.252 . Near SEMA6A 1.47E-02 1.17E-03 7.44E-01 3.19E-06 4.10E-01 3.50E-05 8.23E-01 2.13E-02 2.33E-01 1.480 0.101 0.222 -0.069 0.241 0.269 0.254 0.249
Openness to Experience 7 17,133,514 rs7801891 0.085 . . 2.04E-02 1.51E-03 8.19E-01 4.91E-08 9.33E-02 1.05E-07 2.24E-01 3.37E-02 2.35E-01 -2.020 0.798 -0.243 0.144 0.118 0.059 0.129 0.055
Hostility 7 100,624,309 rs11772086 0.167 INT MUC12 9.39E-03 1.42E-02 2.03E-01 3.07E-07 3.10E-01 6.54E-05 4.19E-01 1.35E-03 5.06E-01 -1.640 0.470 -0.328 0.046 0.199 0.147 0.185 0.146
Agreeableness 7 150,652,419 rs876088 0.146 INT KCNH2 1.55E-03 9.84E-04 2.05E-01 9.69E-08 6.54E-01 2.15E-06 7.05E-01 8.43E-03 7.81E-01 -2.160 0.222 -0.278 0.022 0.180 0.124 0.183 0.116
Openness to Experience 8 18,199,560 rs34290224 0.065 . . 1.08E-01 2.01E-02 9.66E-01 7.65E-08 1.07E-02 7.29E-05 3.32E-01 2.74E-04 1.39E-02 -1.720 0.776 -0.535 0.283 0.078 0.054 0.069 0.059
Vulnerability to Stress 10 63,413,315 rs7907869 0.496 . . 4.34E-05 3.24E-03 4.42E-03 4.11E-08 5.21E-01 7.94E-05 9.89E-01 1.24E-04 4.18E-01 -1.920 0.007 -0.379 -0.044 0.721 0.349 0.723 0.312
Vulnerability to Stress 10 63,416,969 rs1456280 0.496 . . 2.21E-04 5.46E-03 1.38E-02 1.20E-07 7.74E-01 9.58E-05 8.32E-01 3.31E-04 6.07E-01 1.900 -0.104 0.355 0.027 0.273 0.644 0.270 0.679




Table A13. Top GWAS Results of Bivariate EA Analyses for All Neuroticism Domains and Facets Meta-analyzed with Results 
from GWAS of CaD.  
 
 
Abbreviations: Chr, chromosome; Pos, position of SNP on chromosome; SNP, unique dbSNP marker ID; Fxn, function (“INT” = intron, 
“.” = intergenic); Gene, EntrezGene abbreviation; Meta All, p-values of meta-analysis of all four data sets; Meta NEO, p-values of NEO 
AA x EA meta-analysis; Meta CaD, p-values of CaD AA x EA meta-analysis; Meta AA, p-values of NEO and CaD AA meta-analysis; 
Meta EA, p-values of NEO and CaD EA meta-analysis; NEO AA, p-values of NEO AA GWAS; NEO EA, p-values of NEO EA GWAS; 
CaD AA, p-values of CaD AA GWAS; CaD EA p-values of CaD EA GWAS 
 
Trait Chr Pos SNP Global Freq Fxn Gene Meta All Meta NEO Meta CaD Meta AA Meta EA NEO AA NEO EA CaD AA CaD EA NEO AA B Disc AA B CaD AA B CaD EA B NEO AA FreqNEO EA Freq CaD AA Freq CaD EA Freq
Neuroticism 2 54,275,162 rs13414393 0.441 INT LOC100506338 2.33E-05 9.62E-02 2.44E-05 9.59E-01 2.58E-08 3.05E-01 2.47E-04 1.85E-01 2.52E-05 -0.292 1.360 0.109 0.213 0.418 0.446 0.415 0.466
Neuroticism 2 54,301,064 rs6545384 0.409 INT LOC100506338 1.35E-06 1.75E-03 2.26E-04 2.68E-01 5.20E-08 4.82E-01 8.70E-05 3.74E-01 1.10E-04 -0.209 -1.490 -0.079 -0.194 0.322 0.485 0.329 0.465
Neuroticism 2 54,312,153 rs1058320 0.436 . . 3.88E-05 3.05E-02 3.17E-04 9.86E-01 5.28E-08 5.90E-01 1.09E-04 4.95E-01 9.44E-05 0.158 -1.470 -0.057 -0.196 0.380 0.489 0.392 0.467
Neuroticism 2 54,313,836 rs7591194 0.435 . . 2.07E-05 2.04E-02 2.61E-04 8.50E-01 4.20E-08 7.41E-01 1.09E-04 4.85E-01 7.66E-05 0.097 -1.470 -0.059 -0.198 0.377 0.490 0.389 0.468
Neuroticism 2 54,314,610 rs7560947 0.425 . . 9.96E-06 1.99E-02 1.12E-04 6.34E-01 5.18E-08 7.56E-01 1.13E-04 2.60E-01 9.03E-05 0.092 -1.460 -0.095 -0.197 0.355 0.487 0.370 0.467
Neuroticism 2 54,328,837 rs10207537 0.437 . . 4.79E-06 1.10E-02 1.06E-04 5.18E-01 3.73E-08 9.14E-01 7.71E-05 2.51E-01 8.89E-05 0.031 -1.500 -0.096 -0.196 0.378 0.490 0.384 0.475
Neuroticism 2 54,343,108 rs9808326 0.429 INT ACYP2 1.80E-05 3.14E-02 1.19E-04 6.78E-01 1.00E-07 6.95E-01 2.27E-04 2.59E-01 9.78E-05 0.113 -1.390 -0.095 -0.195 0.368 0.483 0.377 0.468
Vulnerability to Stress 7 75,607,155 rs76021834 0.243 INT POR 5.34E-06 4.69E-03 3.40E-04 6.59E-01 1.58E-08 5.10E-01 4.32E-04 9.16E-01 9.58E-06 -0.370 -1.760 0.011 -0.236 0.201 0.269 0.202 0.278
Anxiety 7 75,611,149 rs10954732 0.435 INT POR 3.67E-07 3.57E-02 6.36E-07 3.57E-02 8.87E-07 2.89E-01 4.89E-02 4.38E-02 3.17E-06 -0.275 -0.661 -0.160 -0.242 0.576 0.340 0.571 0.324
Vulnerability to Stress 7 75,611,149 rs10954732 0.435 INT POR 8.72E-07 6.38E-02 6.36E-07 2.76E-01 2.49E-08 8.04E-01 2.11E-03 4.38E-02 3.17E-06 0.106 -1.470 -0.160 -0.242 0.576 0.340 0.571 0.324
Vulnerability to Stress 7 75,611,355 rs2286821 0.442 INT POR 3.71E-06 1.22E-01 1.14E-06 5.06E-01 2.72E-08 5.53E-01 2.68E-03 7.76E-02 2.68E-06 0.253 -1.440 -0.140 -0.243 0.587 0.341 0.586 0.326
Vulnerability to Stress 7 75,611,756 rs3815455 0.237 INT POR 3.30E-05 1.84E-02 5.13E-04 7.42E-01 1.78E-07 6.99E-01 1.83E-03 9.62E-01 2.81E-05 -0.221 -1.560 -0.005 -0.222 0.185 0.274 0.181 0.280
Vulnerability to Stress 7 75,612,803 rs41301394 0.222 INT POR 4.99E-04 1.56E-01 6.12E-04 5.34E-01 2.47E-07 4.12E-01 2.18E-03 9.86E-01 3.31E-05 0.481 -1.550 -0.002 -0.222 0.159 0.267 0.153 0.273
Vulnerability to Stress 7 75,613,998 rs4732514 0.443 INT POR 4.67E-06 5.48E-02 8.30E-06 4.11E-01 8.46E-08 9.16E-01 2.58E-03 1.55E-01 9.23E-06 0.045 -1.440 -0.112 -0.229 0.591 0.342 0.584 0.327
Extraversion 7 84,952,631 rs12534830 0.244 . near SEMA3D 1.49E-05 2.63E-01 1.19E-06 9.02E-01 1.73E-08 1.36E-01 7.56E-04 4.52E-02 6.20E-06 0.725 -1.480 -0.257 -0.260 0.113 0.343 0.117 0.342
Impulsiveness 7 84,952,631 rs12534830 0.244 . near SEMA3D 6.45E-08 6.81E-03 1.19E-06 4.34E-03 2.80E-06 4.08E-02 7.64E-02 4.52E-02 6.20E-06 -1.050 -0.740 -0.257 -0.260 0.113 0.343 0.117 0.342
Extraversion 7 84,995,484 rs12536813 0.226 . near SEMA3D 4.29E-05 3.36E-01 2.93E-06 8.45E-01 2.18E-08 1.25E-01 1.46E-03 1.20E-01 4.07E-06 0.921 -1.410 -0.233 -0.266 0.083 0.335 0.086 0.333
Impulsiveness 7 84,995,484 rs12536813 0.226 . near SEMA3D 2.12E-06 5.45E-02 2.93E-06 8.10E-02 1.86E-06 3.27E-01 7.30E-02 1.20E-01 4.07E-06 -0.611 -0.757 -0.233 -0.266 0.083 0.335 0.086 0.333
Anxiety 14 92,871,852 rs4904893 0.399 INT SLC24A4 5.73E-07 9.07E-05 1.41E-03 3.70E-02 1.48E-06 9.96E-02 5.27E-05 2.00E-01 2.75E-03 -0.422 -1.450 -0.107 -0.148 0.422 0.379 0.425 0.381
Vulnerability to Stress 15 40,153,847 rs275747 0.201 INT GPR176 9.83E-07 2.62E-02 4.09E-06 1.98E-02 8.08E-06 1.55E-01 8.04E-02 5.27E-02 2.04E-05 -0.670 -1.360 -0.181 -0.338 0.350 0.093 0.342 0.089
Impulsiveness 15 40,155,759 rs8027511 0.0889 INT GPR176 1.07E-05 3.92E-01 2.03E-07 6.12E-01 6.78E-08 8.56E-01 1.35E-01 3.09E-01 2.00E-08 0.072 -0.964 -0.115 -0.471 0.135 0.062 0.121 0.056
Impulsiveness 15 40,194,134 rs189936 0.108 INT GPR176 1.37E-04 1.43E-01 1.26E-04 8.51E-01 1.78E-07 6.12E-01 5.43E-03 7.49E-01 9.06E-06 0.189 -1.840 -0.036 -0.398 0.179 0.063 0.167 0.056
Depression 15 62,584,178 rs1818320 0.0567 . . 1.40E-04 2.02E-02 2.38E-03 9.45E-01 3.20E-07 6.06E-01 3.50E-03 4.63E-01 2.69E-05 -0.328 -2.230 0.134 -0.423 0.061 0.057 0.062 0.051
Depression 15 62,587,650 rs11856956 0.0543 . . 8.83E-05 1.82E-02 1.61E-03 8.80E-01 9.72E-08 7.51E-01 1.36E-03 5.34E-01 2.02E-05 -0.215 -2.390 0.115 -0.423 0.052 0.059 0.057 0.052
Depression 15 62,596,220 rs10851713 0.0595 . . 8.12E-05 5.29E-02 3.51E-04 9.93E-01 1.79E-07 8.31E-01 1.58E-03 7.85E-01 3.25E-05 0.136 -2.270 -0.044 -0.419 0.061 0.062 0.070 0.052
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